Trading Analysis Report: ADBE¶

Analysis date: 2026-10-21
Rating: Hold
Generated: 2026-10-21 13:18:59
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 254.62 Price As Of: 2026-10-21

ADBE (Adobe Inc., NMS): Technical Analysis Report¶

1. Data integrity notes¶

The verified snapshot and the indicator tools agree. RSI is 56.37, MACD histogram is +2.75 and ATR is 8.53 in both.
The 2026-10-21 bar looks incomplete. Its volume is 2,105,356, against a typical 3–6M for recent sessions. The OBV tool implies a volume of 2,105,670 for the same day. The 314-share difference is tiny, but it suggests the bar was still updating. Treat today's close, volume and OBV as provisional.
The tools give no earnings calendar or news, so I can't attribute any price move to a catalyst.
I did not pull +DI/−DI, so I can't say from ADX which side is dominant.

2. Indicator selection¶

I chose eight indicators, one or two per category, to avoid redundancy. The 50 SMA, 200 SMA, 10 EMA and Bollinger bands come from the verified snapshot.

Role	Indicator	Why
Trend (multi-timeframe)	supertrend	Gives weekly, monthly and daily direction plus stop levels.
Trend strength	adx	Shows whether trend-following signals are reliable.
Momentum	macdh, rsi	The histogram shows momentum change early. RSI gives the overbought/oversold read.
Volatility	atr (plus snapshot Bollinger)	Used for stop distance and sizing.
Volume	obv	Checks whether volume confirms the rebound.
Exhaustion	td_9	Shows how far the current run is along a DeMark count.
Stretch	z_score	Measures mean-reversion pressure on three timeframes.

3. Price context (252 sessions in the data)¶

The CSV window starts on 2025-10-21. Its highest close is 359.91 on 2025-10-28. Its lowest close is 193.41 on 2026-06-25, with an intraday low of 190.12 on 2026-06-18.
The stock fell from the mid-$300s to below $200 through several gap-downs on heavy volume:
2026-03-13: close 249.32 on 17.4M shares.
2026-06-11/12: closes of 218.80 and 204.02, with 25.0M shares on 06-12.
Heavy-volume gaps also show up on 2025-12-11 (10.2M), 2026-09-10 (10.4M) and 2026-09-11 (10.8M). They fall roughly a quarter apart. That is consistent with earnings-driven moves, but I can't confirm it, so check an earnings calendar separately.
From the June low the stock recovered to a Sept high area (close 292.79 on 08-31; Sept 4 close 266.51 after the pullback began). It then fell to a close of 231.01 on 09-28 (intraday low 224.67). It has since rebounded to 254.62.
The structure is a higher low (231.01 versus 193.41) but still a lower high (292.79 versus 359.91 a year earlier).
Current close versus those reference points, from my arithmetic on the CSV:
About 31.7% above the 06-25 closing low.
About 29.3% below the 2025-10-28 closing high.
Recent impulse: 10-15 closed at 251.67 (+4.6% on 6.6M shares) and 10-20 at 256.73 (+3.9%). Today's close of 254.62 gave back part of that.

4. Trend analysis¶

Moving averages (snapshot): - Close 254.62 sits between the two key averages, which are bunched together: - 50 SMA is 255.67, so price is about 1.05 below it (−0.41%). - 200 SMA is 252.93, so price is about 1.69 above it (+0.66%). - The 10 EMA is 247.16, about 3% below price, so short-term trend slope is positive. - The 50 SMA is currently above the 200 SMA, with a spread of only 2.74. I haven't verified when they crossed. Given how far the stock fell before the recovery, don't treat this as a classic bullish golden-cross signal. - Price is pinned inside a tight band of averages, which signals indecision.

SuperTrend (weekly > monthly > daily): - Weekly (primary): UP. The trailing stop is 206.08, and price is 23.55% above it. - Monthly (regime): DOWN. The stop is 401.26, and price is 36.55% below it. The long-term regime is still bearish. - Daily (timing): DOWN. The stop is 256.93, and price is 0.90% below it. Yesterday's close of 256.73 also stayed under that line. - By the tier-weighting rule, the primary (weekly) trend is up inside a bearish monthly regime. The daily trend is on the verge of flipping. - A daily close above about 256.93 would flip the daily line. That assumes the line doesn't move first, and I haven't verified how it will ratchet.

ADX: 13.14, which means no trend. - ADX peaked at 31.89 on 09-29 during the selloff and fell to 9.49 on 10-19. It has ticked up to 13.14 since. - It is well below the 20 threshold, so the market is range-bound or trendless. - Trend-following signals such as MA crosses and SuperTrend flips are less reliable in this state. Treat the daily SuperTrend flip as unconfirmed until ADX recovers toward 20 or higher.

5. Momentum¶

MACD (snapshot and histogram): - The MACD line is −0.08, the signal line is −2.84, and the histogram is +2.75. - The histogram was −3.77 on 09-22 and turned positive on 10-08 (+0.19). It has risen to +2.75, so downside momentum has fully unwound. - The MACD line is still marginally below zero. A cross above zero would be a further bullish step. - The histogram gain from 10-20 (2.60) to 10-21 (2.75) is small, so acceleration is slowing.

RSI: 56.37. - It bottomed at 34.51 on 09-28, crossed back above 50 on 10-15, and peaked at 58.19 on 10-20. - That is neutral-to-constructive and not overbought. RSI has room to run before it hits 70, but it hasn't confirmed a strong uptrend.

6. Volatility and risk sizing¶

Bollinger bands (snapshot): upper 254.98, middle 241.04, lower 227.11.
Close is 0.36 below the upper band, about 99% of the way from lower to upper band.
Today's high of 257.63 went above the band, but the close finished just under it.
The bands are about 27.9 wide in total, so there is room for a move either way.
ATR: 8.53, or about 3.35% of price. It has eased from 10.41 on 09-22, so volatility is contracting.
Practical stop distances from the current close (my arithmetic):
1×ATR is about 246.09.
2×ATR is about 237.56.
The daily SuperTrend stop is very tight (0.90% away), while the weekly stop is very wide (23.55%). That mismatch makes position sizing awkward. A stop based on ATR or on the key averages is more practical than either SuperTrend level.

7. Volume (OBV)¶

OBV is −201.0M, and its absolute level is meaningless. The slope matters.
Over the 30-day window it ranged from −218.2M (09-28, at the price low) to −198.9M (10-20, the window high).
It has recovered about 17M from the low, so volume supports the bounce.
It is only marginally above the 09-21 reading of −202.7M, even though price is about 2% higher than that day's close of 249.52. Participation is modest, not decisive.
Confirmation would be OBV breaking above the −198.9M window high on a push through resistance. Without that, a breakout would lack volume support.

8. Exhaustion and stretch¶

TD-9: - Daily is −5, a sell-setup 5 of 9. - Weekly is −1 and monthly is −1. - The daily count is mid-way, not at exhaustion. By the weighting rule, the weekly and monthly counts at 1 carry more weight and show no exhaustion. - My own check from the closes matches the tool's count of 5. A completed daily 9 would need four more closes above the close four bars earlier:

Session	Close must exceed
10-22	245.20
10-23	247.09
10-26	256.73
10-27	254.62

Only the last two thresholds are demanding, and a lower close in between would reset the count.

Z-score (20-period): - Weekly is +0.51 (near the mean). - Monthly is −0.89 (near the mean, below it). - Daily is +1.95, close to the |2| stretch threshold. - The stretch is a short-term, daily-only signal. It lines up with the price touching the upper Bollinger band. The weekly and monthly readings show no larger overextension.

9. Confluence and scenarios¶

Resistance cluster at 254.98–257.63 (all within about 1.2% of the close): - 254.98: upper Bollinger band. - 255.67: 50 SMA. - 256.73: 10-20 close. - 256.93: daily SuperTrend line. - 257.63: today's high.

Beyond that, the next reference points are the 2026-09-04 and 09-14 closes of 266.51 and 265.60.

Support, nearest first: - 252.93: 200 SMA. - 247.16: 10 EMA. - 241.04: Bollinger middle. - 231.01: 09-28 closing low (intraday low 224.67 that day). - 227.11: lower Bollinger band. - 206.08: weekly SuperTrend stop.

These are reference levels from the indicators and price history. I have not shown that price has bounced at any of them in the past.

Scenarios: 1. Bullish continuation. A daily close above about 257 would clear the 50 SMA, upper band and daily SuperTrend together. - Confirmation would be ADX rising toward 20 or more, OBV above −198.9M, and the MACD line crossing above zero. - The next reference zone is about 265–267. - A move through the cluster on weak volume would be less trustworthy. 2. Rejection and pullback. Today's close sits at the cluster with a daily z-score near 2 and a daily TD count of 5 (a count that could keep building). - A first pullback target is the 10 EMA at 247.16. - Losing the 200 SMA and the 10 EMA would bring the Bollinger middle at 241.04 into play. 3. Range-bound chop (the base case given ADX). With ADX at 13, rotation inside roughly 231–267 is the default state until a trend develops.

10. Summary read¶

Bullish elements:
The weekly SuperTrend is up.
The MACD histogram is positive and rising.
RSI is above 50.
OBV has recovered from its low.
Price is above the 200 SMA and the 10 EMA.
The lows are higher than in June.
Cautionary elements:
ADX shows no trend.
The daily and monthly SuperTrend are both down.
Price is pressed against a dense resistance cluster.
The daily z-score is near 2.
OBV confirmation is only marginal.
The 10-21 bar is provisional.
The tools support a neutral-to-modestly-constructive near-term picture inside a still-bearish long-term regime. The decision point is how price reacts around 255–257. I leave the trade decision to the next agent.

11. Summary table¶

Item	Reading	Interpretation
Close (2026-10-21)	254.62	Verified; bar may be incomplete
10 EMA / 50 SMA / 200 SMA	247.16 / 255.67 / 252.93	Price between the 50 and 200 SMA, above the 10 EMA
SuperTrend weekly	UP, stop 206.08 (+23.55%)	Primary trend up
SuperTrend monthly	DOWN, stop 401.26 (−36.55%)	Bearish long-term regime
SuperTrend daily	DOWN, stop 256.93 (−0.90%)	Near a flip; needs a close above the line
ADX	13.14 (peak 31.89 on 09-29)	No trend; breakouts less reliable
MACD / signal / histogram	−0.08 / −2.84 / +2.75	Bullish crossover; zero-line cross pending
RSI	56.37	Neutral-to-constructive; not overbought
Bollinger (lower / mid / upper)	227.11 / 241.04 / 254.98	Close at the upper band
ATR	8.53 (about 3.35% of price)	Volatility contracting; 2×ATR below is about 237.56
OBV	−201.0M (30-day range −218.2M to −198.9M)	Mild confirmation; no strong breakout in volume
TD-9 (W / M / D)	−1 / −1 / −5	No exhaustion; daily at 5 of 9
Z-score (W / M / D)	+0.51 / −0.89 / +1.95	Daily nearly stretched; higher timeframes near the mean
Resistance	254.98, 255.67, 256.93, 257.63, then about 265–267	Dense cluster directly overhead
Support	252.93, 247.16, 241.04, 231.01, 227.11, 206.08	Reference levels only; no bounces claimed
Key caveats	ADX low, 10-21 bar provisional, no catalyst data, DI not pulled	Confirm before acting

Sentiment Analyst¶

Overall Sentiment: Mildly Bullish (Score: 6.0/10) Confidence: Low

SCOPE AND DATA LIMITS: This covers ADBE (Adobe Inc.) for 2026-10-14 to 2026-10-21. Reddit was disabled by config, so one of three sources is missing entirely, which is why confidence is low. The news block is headlines only, with no body text or timestamps, so I cannot verify what any article says beyond its title. StockTwits supplied 30 messages spanning only about 27 hours (2026-10-20 15:41Z to 2026-10-21 19:08Z), so it reflects the last day or two and not the full 7-day window. No price, fundamental or short-interest data was provided. Price levels, buyback figures and the earnings date below are user-reported on StockTwits and unverified.

1) SOURCE-BY-SOURCE BREAKDOWN

News (17 headlines, Yahoo Finance). About 7 headlines name ADBE directly: Simply Wall St 'Adobe deepens AI partnerships across creative and customer experience tools'; Zacks 'Adobe is attracting investor attention'; 24/7 Wall St 'Wall Street has its eyes on Adobe'; StockStory 'monday.com, Adobe, DocuSign, Intuit, MongoDB stocks trade up'; 24/7 Wall St 'Salesforce retreats 2% on $5.66B Braze deal, even as ServiceNow and Adobe gain 2%'; Simply Wall St 'Meta earnings puts Adobe stock and AI ad software names in focus'; and a GlobeNewswire digital-signature market report that merely profiles Adobe. Another 5 to 6 are sector context: the Salesforce/Braze deal (IBD, Stocktwits, Trefis), Citi's Tyler Radke on 'AI splitting software into winners and losers', MarketBeat's '4 stocks with demand so sticky that the AI sell-off barely touched them', and StockStory's '1 Nasdaq 100 stock to own for decades and 2 we avoid'. The headlines do not say whether ADBE is in those last three. Roughly 4 headlines are noise (Northern Trust Q3 results, software-defined data center market, retail analytics market, Billion Dollar Boy creator marketing). The overall news tone is constructive-to-neutral and mostly sector-driven. The one hard event is Salesforce agreeing to buy Braze for about $5.7B in cash. Jefferies reportedly says this could spark more software takeovers, which supports a re-rating or take-out narrative for beaten-down software. ADBE was reported up about 2% alongside ServiceNow while Salesforce fell about 2% on the deal. The 'AI sell-off' wording confirms the backdrop: software was sold on AI-disruption fears and is now being re-examined.

StockTwits (30 messages): Bullish 12 (40%), Bearish 1 (3%), Unlabeled 17. Among labeled posts that is 12 of 13 (about 92%) bullish, which nominally sits in the over-extension zone. The labeled sample is tiny, though, and quality is weak. (a) @anthealopez wrote 6 of the 12 bullish posts, all short cheerleading ('Propping UP!!!', 'Patienceeeee', 'So boring hahahah'), and one of them also cashtags APP, COHR and DOCN. (b) @ShadowBanningIsBad's bullish tag ('PUMP IT... a little more fat and the bears can feed') comes from a user who says ADBE's 'business model was destroyed' and would 'love to see near 289 would be a great price to short'. This is effectively a bearish or short-bias poster. © @Prady's bullish tag sits on 'still hanging on to this turd since last year', which reads as a complaint, and the same user later asks where the open-market insider buys are. (d) @KoolMandate's bullish tag is about $INTU, not ADBE. Excluding these, genuine independent ADBE-bullish posts are about 3: @Aegis6 ('higher highs and higher lows. 300 by end of month'), @LGDRYInvestor (EPS growth means the market 'can't ignore it forever') and @AVGOmysugardaddy ('Happy ADBE is doing well'). The only Bearish tag is @TheWinningStock's emoji-only post with no argument. The unlabeled posts add substance, covered under themes below. Net: a retail tone tilted positive, driven by recent price strength, but shallow and partly promotional. It is not euphoric, since many posters expect 'sideways' or 'boring' action and hold from higher prices.

Price and technical context from StockTwits (unverified): @TopOptionAlert reports ADBE at 247.09 on Oct 19 and 256.73 on Oct 21 (+3.9%) and a Nov-20 255 call alert with objectives at 262 then 275 and invalidation at 241.51. @johh22 sold some shares at 256.22 and holds others bought at 270 that he would 'completely bail' on near 285. @djig says 'give me 300 and I am out'. @ElliottwaveForecast calls this a corrective bounce toward 256.35 to 265.4 that 'should fail below September-2026 peak to extend lower within weekly zigzag correction'. @BioEu notes several upside gaps left in a few days and asks whether they get filled. Shares outstanding per @stockmando: 420M (Q3'25), 413M, 406M, 399M, 391M (Q3'26), about 7% lower over four quarters, with 383M projected next quarter. @TopOptionAlert says Adobe reports December 9, about 7 weeks out. That date is not confirmed in the news feed.

Reddit: disabled by config. No signal from r/wallstreetbets, r/stocks or r/investing, so no cross-check on whether the retail mood extends beyond StockTwits.

2) CROSS-SOURCE DIVERGENCES AND ALIGNMENTS Alignment: News and StockTwits both frame ADBE as part of a 'beaten-down software rebound'. News shows ADBE and peers trading up on the Braze deal and a possible M&A wave. StockTwits users echo it ('market has swung WAY too far against software stocks' from @Ashton_1nvests, naming ADBE, CRM and NOW; @FinnishSpeculator likes HUBS, MNDY, INTU and ADBE as SaaS 'still well below highs'). Divergences: (i) Many retail posters present the long thesis as valuation, cash flow and buybacks, but the prompt contains no fundamentals to verify it. (ii) The news-side AI framing is two-sided (winners vs losers) while the retail bear case is blunt ('business model destroyed'). Neither source settles which side ADBE falls on. (iii) Bullish price targets (300 by month-end, roughly +17% from about 256) conflict with the technical and holder-behavior picture, where trapped holders from 270 want to exit at 285 to 300 and an Elliott view expects the bounce to fail below the September peak. (iv) The 92% labeled-bullish ratio is higher than the substance of the posts supports, because tags are inflated by one user and sarcastic tagging. The real signal is closer to mildly bullish than to the headline ratio.

3) DOMINANT NARRATIVE THEMES - Software re-rating and 'too far oversold' (news: MarketBeat, Citi, StockStory sector-up; retail: Ashton, FinnishSpeculator, Conor958 arguing ADBE trades at or below fair value and that it was overvalued at 600 in 2021 and 2024). - Software M&A / take-out premium (Salesforce-Braze; Jefferies commentary). - AI as threat vs tailwind (Adobe AI partnerships, Meta earnings read-through for AI ad software, Citi's winners/losers split vs the retail 'destroyed' bear thesis). - Capital return and EPS growth (buyback share-count math, @LGDRYInvestor). - Short-term technicals and options flow (256 to 265 zone, 262/275 objectives, 241.51 invalidation, a bullish call alert, SmartFlowTrading's bullish software options watchlist; its visible portion does not show ADBE among the top picks). - Holder fatigue ('so boring', 'hanging on since last year', trapped at 270) and management friction (no open-market insider buys).

4) CATALYSTS AND RISKS Catalysts: further software M&A read-through; AI partnership and product announcements; AI ad-software read-through from Meta earnings; continued buyback-driven share-count reduction; a decisive break above 262 (the first test cited by options watchers) and then 265; the reported December 9 earnings date (unconfirmed, outside the lookback window); strong options flow in software. Risks: renewed AI-disruption selling across software (Citi's 'losers' side; MarketBeat's 'AI sell-off'); resistance at 256 to 265 and overhead supply at 270 to 300 from trapped holders; an Elliott-style failure below the September 2026 peak; a loss of 241.51 voiding the bullish options setup; short sellers positioning near 289; promotional or coordinated-looking bullish posts overstating retail conviction; no confirmed insider buying; acquirer-style skepticism toward M&A (Salesforce fell about 2% on the Braze deal), which shows the market does not reward all deal news. Missing evidence: Reddit, article bodies, prices, fundamentals and confirmed earnings dates.

5) SUMMARY TABLE | Signal | Direction | Source | Evidence | |---|---|---|---| | Labeled retail skew | Bullish (low quality) | StockTwits | 12 Bullish / 1 Bearish / 17 unlabeled of 30; 6 of 12 bullish from one user; sarcastic or off-ticker tags among the rest | | Short-term momentum | Bullish | StockTwits | About 247.09 (Oct 19) to 256.73 (Oct 21), +3.9%; 'higher highs and higher lows'; upside gaps noted | | Overhead resistance / trapped holders | Cautionary | StockTwits | 256.35-265.4 zone; holders from 270 would exit near 285; 'give me 300 and I am out' | | Elliott corrective view | Mildly Bearish | StockTwits | Bounce within weekly zigzag; should fail below September 2026 peak to extend lower | | Software M&A read-through | Mildly Bullish | News | Salesforce-Braze about $5.7B all-cash; Jefferies says it could spark more software takeovers | | Same-day sector move | Mildly Bullish | News | ADBE and NOW up about 2% while CRM fell about 2%; StockStory lists ADBE among software names trading up | | AI partnerships | Mildly Bullish | News | Simply Wall St: Adobe deepens AI partnerships (headline only) | | AI winners vs losers | Mixed | News | Citi's Radke; MarketBeat 'AI sell-off'; ADBE's placement not stated in headlines | | Buyback / EPS support | Bullish | StockTwits | Shares outstanding 420M to 391M over four quarters (about 7%); unverified | | AI-disruption bear thesis | Bearish | StockTwits | 'Business model was destroyed'; short idea near 289; @TheWinningStock bearish tag | | Insider-buying friction | Mildly Bearish | StockTwits | @Prady asks where the open-market insider buys are | | Options flow / call alert | Mildly Bullish | StockTwits | Nov-20 255C alert, objectives 262/275, invalidation 241.51 | | Earnings catalyst | Pending | StockTwits | December 9 per one user; not in news feed | | Reddit | No data | Reddit | Disabled by config |

OVERALL: Mildly Bullish. The news flow is constructive on software M&A and ADBE's AI partnerships, and retail tilts positive on recent price strength. The read is held back by thin labeled data (13 tags), heavy single-user concentration, headline-only news, no Reddit, no price or fundamental verification, and clear technical resistance and AI-disruption bear arguments. This is a sentiment signal to weigh alongside fundamentals and technicals, not a price call.

News Analyst¶

ADBE (Adobe Inc.) – Weekly News and Macro Report, 2026-10-14 to 2026-10-21¶

1. Data coverage¶

Source	Status
Company news (`ADBE`)	Returned headlines and sources only. There are no article bodies, no per-article timestamps, and no price, volume or earnings figures.
Global news	Returned, but it is mostly tech and commodity noise with little macro content.
FRED macro (fed funds, 10y, CPI, core PCE, unemployment, yield curve, VIX, DGS10)	All failed with `DATA_UNAVAILABLE`. I have no rate, inflation, jobs, curve or volatility readings, and I won't estimate them.
Prediction markets (Polymarket)	Returned for Fed, recession and AI bubble. There are no Adobe-specific markets.

The 7-day and 3-day company news queries returned the same list. I therefore can't tell which headline fell on which day, and the sequencing below is inferred from the headlines.

2. Company-specific read on ADBE¶

Sector M&A is the main catalyst this week. - Salesforce agreed to buy Braze in an all-cash deal of about $5.66–5.7B (IBD, 24/7 Wall St.). - 24/7 Wall St. reported that Salesforce fell about 2% on the news, while ServiceNow and Adobe each gained about 2%. - Jefferies, via Stocktwits, says the deal "could spark more software takeovers." - Braze is a customer-engagement platform, so it competes with Adobe's Experience Cloud and marketing stack. The deal shows large software companies are paying cash for marketing and customer-experience assets. - Trader implication: Adobe's customer-experience business may be seen as a scarce asset in a consolidating field. This is a speculative read, and no headline says Adobe is a target or an acquirer.

Software is trading as an AI winners-and-losers market. - Citi's Tyler Radke says AI is "splitting software into winners and losers." - MarketBeat refers to an "AI sell-off" in software and highlights names with "sticky" demand. - StockStory reported that monday.com, Adobe, DocuSign, Intuit and MongoDB all traded up in the same session. - Adobe has been pulled between two views. One sees it as an AI beneficiary. The other sees it as exposed to generative-AI disruption in creative tools. - The week's moves look like a relief rally for the group. They don't show a settled verdict on Adobe.

Adobe's AI positioning and sentiment - Simply Wall St. says Adobe is deepening AI partnerships across its creative and customer-experience tools. The headline gives no partner names or terms. - Meta's earnings put Adobe and AI ad-software names "in focus." Strong AI-driven ad spend from Meta would favor Adobe's marketing and creator tooling. The headline doesn't give Meta's results. - Zacks ("attracting investor attention") and 24/7 Wall St. ("Wall Street has its eyes on Adobe") point to elevated retail and analyst interest. Neither gives a price target or rating change that I can verify. - A GlobeNewswire market report lists Adobe among the digital signature players alongside DocuSign. It is boilerplate and not a catalyst.

Not found in this week's news: an Adobe earnings release, guidance change, analyst upgrade or downgrade, or specific product launch. Adobe's fiscal Q4 report normally comes in mid-December, so the next hard fundamental catalyst is about two months away. I haven't verified the exact date.

3. Broader market context¶

Equities were firm going into mega-cap earnings. MT Newswires reported "Stocks Rise Pre-Bell as Traders Await Meta, Tesla Earnings."
IBM's Q3 earnings preview points to roughly 8% EPS growth expected. IBM is a read-through for enterprise AI and software spending.
Gold futures edged up as oil slipped (WSJ). That is a mild defensive and disinflationary signal, but I have no price levels.
The AI trade shows some strain, with headlines on a "vanishing" model moat, IonQ down by half in a year, and Rigetti's drop. This feeds the AI-disruption debate for application software.

4. Market-implied probabilities (Polymarket)¶

Event	Implied probability	Volume	Notes
No Fed rate cuts in 2026	97%	~$9.0M	Deep market. Up 0.2pp on the week.
6, 9, 10, 11, or 12+ cuts in 2026	0%	$4–5M each	Effectively ruled out.
Fed cuts 25bp at December 2026 meeting	1%	~$0.97M
Fed holds in December	18%	~$0.97M	Down 1.0pp on the week.
Fed hikes 25bp in December	78%	~$0.97M	Surprising, see caveat below.
Fed hikes 50bp+ in December	2%	~$0.59M
US recession by end of 2026	8%	~$2.3M	Low.
AI bubble bursts in 2026	9%	~$2.5M	Up 2.9pp on the week.
AI bubble bursts by June 30, 2027	20%	~$36K	Thin market.

Caveat on the 78% December hike. This is a thin, roughly $1M market, and I can't cross-check it. The FRED calls that would show the current policy rate, inflation and the curve all failed. The 97% "no cuts in 2026" market is consistent with a hawkish or on-hold Fed. The hike probability is a large claim that other desks should confirm before acting on it.
If the hike pricing is right, it is a headwind for long-duration growth and software multiples, because higher discount rates compress valuations. Adobe has traditionally been a high-multiple, cash-flow-heavy name, so it is sensitive to rates.
The 8% recession odds suggest the market is pricing a hawkish-but-not-recessionary path. That supports enterprise software demand, but it makes rate risk the main macro threat.
The AI-bubble odds are low in absolute terms but rose 2.9pp in a week. That is worth watching for a tech-wide sentiment shift.

5. Trading takeaways¶

Sector M&A and the "software rerating" narrative are supportive. Adobe rose about 2% on the Salesforce–Braze news. That may fade if no follow-on deals appear.
Rates are the main macro risk, but the evidence is incomplete. The December hike pricing comes from one thin market. Verify it against fed funds futures and the CPI/PCE prints before positioning.
The AI disruption debate is unresolved. Citi's winners-and-losers framing implies high dispersion within software. Adobe is likely to move on AI-monetization evidence, not on sector beta alone.
Watch these catalysts: other software M&A, Meta and other mega-cap ad-spend commentary, IBM's results, any Adobe product or partnership details, and the December FOMC and Adobe Q4 earnings.
Event risk: the 9% AI-bubble odds and the 78% hike pricing are the two tails that could hit ADBE.

6. Gaps for the next analyst¶

Get ADBE price, volume and technicals. None were available to me.
Get current fed funds, 10-year yield, CPI, core PCE, unemployment, yield curve and VIX from another source.
Read the actual articles for the Adobe AI partnerships, the Zacks and 24/7 Wall St. pieces, and the Meta earnings read-through.
Confirm the Adobe fiscal Q4 earnings date.

Summary table¶

Category	Key point	Evidence	Trading relevance
Sector M&A	Salesforce buys Braze for about $5.7B in cash.	IBD, 24/7 Wall St.	CRM fell about 2%; ADBE and NOW rose about 2%. Possible takeover premium across software.
M&A follow-on	Jefferies sees more software takeovers.	Stocktwits	Speculative. No headline names Adobe as a target or acquirer.
AI narrative	Software is splitting into AI winners and losers.	Citi (Radke), MarketBeat	High dispersion. ADBE needs AI-monetization proof.
Peer moves	monday.com, ADBE, DocuSign, Intuit and MongoDB traded up together.	StockStory	Group relief rally, not Adobe-specific.
Adobe AI partnerships	Deepening across creative and customer-experience tools.	Simply Wall St.	Mildly positive. Terms and partners unknown.
Ad-tech read-through	Meta earnings put Adobe and AI ad software in focus.	Simply Wall St.	Results not provided. Check Meta's ad-spend commentary.
Analyst/retail interest	Elevated attention on ADBE.	Zacks, 24/7 Wall St.	No verified rating or target change.
Company catalysts	No earnings, guidance or rating news this week.	Absent from tool output	Next hard catalyst is likely mid-December Q4 earnings (unverified).
Fed path	97% no cuts in 2026; 78% hike in December; 1% cut.	Polymarket	Rate-hike risk would pressure growth multiples. Thin market, verify.
Recession risk	8% US recession by end of 2026.	Polymarket	Low. Supports enterprise demand.
AI bubble risk	9% burst in 2026 (up 2.9pp); 20% by mid-2027.	Polymarket	Tail risk for tech sentiment.
Macro data	FRED series all failed.	`DATA_UNAVAILABLE`	No rate, inflation, jobs or VIX readings. Source elsewhere.
Cross-asset	Gold edged up as oil slipped.	WSJ headline	Mild defensive and disinflation tilt. No levels.
Other earnings	IBM Q3 preview (about 8% EPS growth), Meta and Tesla pending.	Benzinga, MT Newswires	Enterprise AI and ad-spend read-throughs.

Fundamentals Analyst¶

ADBE (Adobe Inc.) Fundamental Report, as of 2026-10-21¶

Scope note: The tools returned data through the fiscal Q3 2026 filing (quarter ended 2026-08-28). The only insider activity in the past week is routine vesting-type entries dated 2026-10-15. Nothing in the data shows a new filing or event in the last seven days. The report therefore covers the latest filed data plus the 12-month insider record.

1. Company Snapshot¶

Item	Value
Company / Exchange	Adobe Inc. / NMS (Technology, Software – Application)
Market cap	~$99.1B
Implied share price	~$254.6 (P/B 8.46 × book value $30.087 ≈ P/E 14.2 × EPS $17.91)
52-week range	$190.12 – $363.70 (price is ~30% below the high and ~34% above the low, at about the 37^th percentile of the range)
50-day / 200-day average	$255.86 / $253.32 (price sits right on both)
Beta	1.415 (more volatile than the market)
Dividend	None. Capital return is through buybacks.

2. Valuation¶

Metric	Value	Comment
P/E (TTM, GAAP)	14.2x	Low for a software franchise with ~28% net margins
Forward P/E	9.3x	Forward EPS is $27.51 against TTM EPS of $17.91, a 54% gap. This is almost certainly a non-GAAP estimate compared with a GAAP trailing figure, so it is not a growth forecast. I can't confirm the basis from the tool.
PEG	0.59
P/S (calculated)	~3.8x	$99.1B / $25.97B
P/B	8.46x	Inflated by shrinking equity from buybacks
FCF yield (calculated)	~9.4%	$9.35B / $99.1B
EV/EBITDA (calculated)	~10x	EV is about $101.5B. Debt is implied from D/E at about $6.8B, less $4.36B cash. Short-term investments aren't in the data, so EV is slightly overstated.

3. Income Statement Trends (quarterly, $M)¶

Quarters shown are fiscal Q1–Q3 (ending Feb, May, Aug). Q4 (November) columns are absent from the source.

Quarter	Revenue	YoY	Gross margin	Op income	Op margin	Net income	Diluted EPS	EPS YoY
Q1 FY25 (Feb-25)	5,714	+10.3%	89.1%	2,163	37.9%	1,811	4.14
Q2 FY25 (May-25)	5,873	+10.6%	89.1%	2,109	35.9%	1,691	3.94
Q3 FY25 (Aug-25)	5,988	+10.7%	89.3%	2,173	36.3%	1,772	4.18
Q1 FY26 (Feb-26)	6,398	+12.0%	89.6%	2,418	37.8%	1,889	4.60	+11.1%
Q2 FY26 (May-26)	6,618	+12.7%	89.2%	2,238	33.8%	1,712	4.25	+7.9%
Q3 FY26 (Aug-26)	6,760	+12.9%	88.7%	2,354	34.8%	1,827	4.62	+10.5%

Positives - Revenue growth has accelerated. It went from about 10.5% in FY25 to 12.0%, 12.7% and 12.9% across the last three quarters. Q3 revenue was up 2.1% sequentially. - The long-run record is steady. Q3 revenue compounds at about 11% a year over four to five years, from $4.43B in Q3 FY22 and $3.94B in Q3 FY21 to $6.76B now. - Gross margin is still high. It runs about 89%, and TTM gross profit is $23.18B on $25.97B of revenue. - Operating income rebounded in Q3. It rose 5.2% sequentially, and Q3 operating margin of 34.8% matches the snapshot's operating margin exactly.

Concerns 1. Negative operating leverage. Operating expenses (gross profit minus operating income) grew 13.2%, 17.2% and 14.8% in Q1–Q3 FY26. Revenue grew 12.0%, 12.7% and 12.9%. - Operating income growth was +11.8%, +6.1% and +8.3%, all below revenue growth. - Q3 operating margin was down about 150 bp YoY (34.8% vs 36.3%). 2. Cost of revenue is accelerating. Growth went from +6.8% to +12.1% to +18.8% across the three quarters, against +12.9% revenue growth in Q3. Gross margin fell about 60 bp YoY in Q3. The data doesn't give the cause. Higher compute or AI-related delivery costs would be consistent with it, but that is my inference. 3. EPS growth is mostly buyback-driven. - Net income grew only +4.3%, +1.2% and +3.1% in Q1–Q3, while EPS grew +11.1%, +7.9% and +10.5%. - Implied diluted shares fell from about 437M (Q1 FY25) to about 396M (Q3 FY26), a drop of roughly 9.6%. Q3 is down about 6.7% YoY. 4. Weaker conversion below the operating line. Net income was about 77.6% of operating income in Q3 FY26, against about 81.5% a year earlier. The data doesn't show whether tax, interest or other items caused this. 5. Q3 net margin was 27.0%, down from 29.6% a year earlier.

TTM (from the fundamentals snapshot):

Item	Value
Revenue	$25.97B
Net income	$7.28B (28.0% margin)
EBITDA	$9.92B (38.2% margin)
EPS	$17.91

Implied Q4 FY25 revenue is about $6.19B and net income about $1.86B.

4. Balance Sheet (Aug 28, 2026, $M)¶

Item	Aug-25	Feb-26	May-26	Aug-26
Cash & equivalents	4,982	6,332	4,919	4,359
Current assets	9,412	10,386	9,068	9,158
Total assets	28,754	29,704	29,933	29,981
Current liabilities	9,239	11,390	12,078	11,888
Total liabilities	16,984	18,271	18,415	18,217
Stockholders' equity	11,770	11,433	11,518	11,764

Key ratios:

Ratio	Value
Current ratio	0.77
Debt/equity	0.58x (implied debt about $6.8B)
Net debt / EBITDA	~0.25x (calculated)
ROE	61.9%
ROA	20.1%

Observations - Leverage is modest. Net debt is about 0.25x EBITDA, and cash generation is large relative to obligations. - Liquidity is thinner than a year ago. - Cash fell about $1.97B (-31%) from Feb-26 to Aug-26. - Working capital swung from about +$0.17B (Aug-25) to about -$2.7B. - Current liabilities are up 29% YoY. - A large part of current liabilities is probably prepaid-subscription deferred revenue, which is normal for this model. I can't confirm that, because deferred revenue and debt lines aren't in the tool output. - Check whether debt maturities have moved into current liabilities. That would explain the jump. - Equity has shrunk because of buybacks. It peaked at $16.5B in Dec-2023 and is now $11.8B (-29%). That inflates ROE (61.9%) and P/B, so neither is a clean quality or valuation signal.

5. Cash Flow (year-to-date, cumulative, $M)¶

9 months ended	Operating CF	Capex	FCF (calc.)	Investing CF	Financing CF
Aug-2025	6,871	145	6,726	(1,041)	(8,505)
Aug-2026	7,646	180	7,466	(1,908)	(6,814)
YoY	+11.3%	+24%	+11.0%

Q3 standalone operating cash flow was about $2.52B, against $2.20B a year earlier (+14.8%). Q1 was $2.96B and Q2 about $2.17B.
Cash generation is strong and stable. The 9-month FCF margin is about 37.8% (38.3% a year earlier). Capex is under 1% of revenue. The snapshot's TTM FCF is $9.35B, about 128% of net income.
SBC isn't in the retrieved data. FCF is before stock-based compensation, so the gap between FCF and GAAP net income should be checked against SBC and D&A before treating the 128% as pure cash quality.
Capital return is the main use of cash. Financing outflows of $6.8B over nine months were about 89% of operating cash flow. They were $8.5B in the prior-year period, which exceeded operating cash flow.
Annualized, that is roughly 9% of market cap.
It fits the roughly 7% YoY share count reduction.
Cash on hand has fallen as a result, and the Aug-26 balance is lower than in recent quarters.

6. Insider Activity¶

Last week: Only 2026-10-15 entries appear. They have no price or value, so they look like vesting or tax-withholding events, not open-market trades. The entries are: - CEO Narayen: 8,300 shares (indirect) - CFO Day: 2,100 shares - Officers Chakravarthy (3,023), Chen (3,244), Balazs (2,537), Forusz (1,823) and Pentland (1,308)

Open-market trades over the past 12 months (entries with a stated price):

Date	Insider	Action	Shares	Price	Value
2026-07-29	Forusz (Officer)	Sale	416	$264.33	$110K
2026-06-25	Ricks (Director)	Purchase	10,000	$194.51	$1.95M
2026-04-30	Forusz (Officer)	Sale	755	$246.24	$186K
2026-04-28	Narayen (CEO, indirect)	Sale	75,000	$243.19–244.78	$18.27M
2026-04-20	Durn (CFO/COO)	Sale	1,336	$248.02	$331K
2026-01-27	Durn	Sale	1,646	$294.85	$485K
2025-10-31	Forusz	Sale	149	$337.88	$50K

Read-through - Totals. About $19.4M of sales (79,302 shares) against $1.95M of purchases. About 94% of the sales value is the single CEO sale. The remaining sales total about $1.16M and are small and routine. - Director Ricks is the notable buyer. - He bought at $194.51, close to the 52-week low of $190.12. That position is now about 31% in the money. - He also bought 2,250 shares at $443.98 in January 2025, which is deeply underwater. - His blended cost on 12,250 shares is about $240. - He added at the lows, which is a mildly constructive signal. - CEO sale. The April sale was at about $244, roughly 4% below today's price. The data doesn't say whether it was under a pre-arranged 10b5-1 plan. The "Transaction" column is blank throughout, so I can't separate sales, tax withholding, vesting and grants for the unpriced entries. - Possible CFO transition. Daniel Durn appears as CFO through 2026-04-20 (labeled COO on 04-15), and Steven Day appears as CFO from 2026-06-15. This suggests a CFO change in Q2 2026. Verify it against filings. - Director grants. The April 2026 director awards were 900 shares each, against 633 in April 2025. That is consistent with a fixed-dollar grant at a lower share price. This is inference. - Last 90 days. The only priced trade is Forusz's ~$110K sale, so there is no meaningful insider selling pressure.

7. Data Caveats¶

Q4 (November) quarters and fiscal-year totals are missing from the income statement and cash flow data. TTM figures come from the snapshot, and Q4 FY25 is back-solved.
Cash flow figures are cumulative year-to-date, so I derived the standalone quarters.
The data doesn't include debt, deferred revenue, RPO, SBC, share repurchase amounts, ARR or segment data. I flagged where I inferred something that these would settle.
Q1 FY24 shows operating income of $907M and net income of $620M, against about $1.9B and $1.6B around it. That quarter was distorted by a one-off, probably the Figma termination fee (my recollection, not in the data). Exclude it from trend comparisons.
The next earnings report (Q4 FY26 and FY27 guidance) hasn't happened yet. Based on past timing it would fall around mid-December, but that is not in the data.

8. Summary for the Trading Decision¶

Supportive of the stock - Revenue growth is accelerating (12.0% → 12.7% → 12.9%). - FCF is roughly $9.3B (about 9.4% yield), with a ~38% FCF margin and very low capex. - Valuation is low: P/E 14x, EV/EBITDA about 10x, P/S 3.8x. - Net debt is minimal. - The share count is falling about 7% a year. - A director bought near the lows.

Cautionary - Opex and cost of revenue are growing faster than revenue, so margins are slipping (operating margin -150 bp, gross margin -60 bp YoY). - Net income growth is only 1–4% and EPS growth depends on buybacks. - Cash is down 31% in two quarters, the current ratio is 0.77, and the balance sheet is trending toward more current obligations. - Beta is 1.4, the stock fell from $363.70 to $190 over the past year, and it is now flat against its 50- and 200-day averages. - The CEO's $18.3M sale in April and a probable CFO change both need context.

What to watch - Q4 / FY27 guidance (likely December). Check whether the margin trend stabilizes and whether the revenue acceleration holds. - Cost of revenue growth against revenue growth. - Cash and financing. Check whether buybacks continue at ~$2B+ a quarter despite falling cash, and whether debt is being refinanced. - Insider filings, especially any further open-market sales by the CEO or the CFO change details.

Key Points Table¶

Category	Metric	Value	Signal
Valuation	P/E (TTM GAAP) / Forward P/E	14.2x / 9.3x	Cheap, but forward is likely non-GAAP
Valuation	PEG / P/S / EV/EBITDA	0.59 / ~3.8x / ~10x	Low for the margin profile
Valuation	FCF yield	~9.4%	Strong
Price	Price vs 52-week range	~$254.6 in $190.12–$363.70	Mid-range, ~30% below the high
Technical	vs 50/200-day averages	At both ($255.86 / $253.32)	Neutral
Growth	Revenue growth (Q1→Q3 FY26)	12.0% → 12.7% → 12.9%	Accelerating
Growth	Q3 FY26 revenue	$6.76B (+12.9% YoY)	Strong
Profitability	Gross margin (Q3)	88.7% (-60 bp YoY)	Slight compression
Profitability	Operating margin (Q3)	34.8% (-150 bp YoY)	Compression
Profitability	Opex growth vs revenue growth	13–17% vs 12–13%	Negative operating leverage
Earnings quality	Net income growth (Q1–Q3 FY26)	+4.3% / +1.2% / +3.1%	Weak
Earnings quality	EPS growth (Q1–Q3 FY26)	+11.1% / +7.9% / +10.5%	Buyback-driven
Earnings	Q3 FY26 diluted EPS	$4.62
Earnings	TTM EPS	$17.91
Cash flow	9-month operating CF / FCF	$7.65B / ~$7.47B (+11%)	Strong and stable
Cash flow	FCF margin	~38%	Strong
Cash flow	TTM FCF vs net income	$9.35B vs $7.28B (~128%)	Check SBC
Capital return	9-month financing outflow	$6.8B (~89% of operating CF)	Aggressive buybacks
Capital return	Implied share count	~437M → ~396M in six quarters	Falling
Balance sheet	Cash	$4.36B (-31% since Feb-26)	Declining
Balance sheet	Current ratio	0.77	Low
Balance sheet	Working capital	~-$2.7B (vs +$0.17B a year ago)	Deteriorated
Balance sheet	Debt/equity / net debt/EBITDA	0.58x / ~0.25x	Manageable
Balance sheet	Equity	$11.76B (-29% from the Dec-23 peak)	ROE inflated
Returns	ROE / ROA	61.9% / 20.1%	Strong
Insiders	Past week	Vesting-type entries only (10/15)	Neutral
Insiders	12-month sales / purchases	~$19.4M (94% one CEO sale) / $1.95M	Mixed
Insiders	Director Ricks	Bought 10,000 sh at $194.51 on 2026-06-25	Constructive
Insiders	CEO Narayen	Sold 75,000 sh (~$18.3M) at ~$244 on 2026-04-28	Cautionary, context unknown
Insiders	CFO	Durn through April, Day from June	Verify transition
Risk	Beta	1.415	Higher volatility
Catalyst	Q4 FY26 / FY27 guidance	Not yet reported, likely mid-December	Key event

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Case for ADBE: A Growing, Cash-Generating Franchise at a Discounted Price

I'll start with what the market is pricing in and then show where the data disagrees.

1. The market is pricing a business in decline, but the numbers show one that's accelerating¶

ADBE is about 29% below its October 2025 closing high and trades at roughly 14x trailing GAAP earnings. That is a price for a company whose core is being disrupted. The latest results say otherwise:

Revenue growth is accelerating. It went from about 10.5% through FY25 to 12.0%, 12.7% and 12.9% across the last three quarters. Q3 revenue was $6.76B, up 12.9% YoY.
Gross margin is still 88.7%. A business that generative AI was commoditizing would show pricing pressure, and this doesn't.
A disrupted franchise doesn't speed up. If the "business model was destroyed" thesis from StockTwits were right, growth would be fading by now. It's doing the opposite.

I'll concede that revenue can lag the damage. But the burden of proof has shifted to the bears, and the reported numbers don't support them.

2. The cash flow is the core of the thesis¶

TTM free cash flow is about $9.35B on a $99B market cap, a roughly 9.4% FCF yield.
Nine-month FCF is up 11% YoY, with a ~38% FCF margin and capex under 1% of revenue.
Q3 operating cash flow was up about 14.8% YoY.
EV/EBITDA is about 10x, and net debt/EBITDA is only about 0.25x.

Applying an 8% FCF yield, still generous for a business this capital-light, gives about $300 per share. That is an illustration and not a forecast, but it sits below where the stock traded in January 2026. The market doesn't have to love Adobe for the stock to work. It only has to stop pricing a collapse.

3. Buybacks at this price create real value¶

The bear will say EPS growth is "just buybacks." Look at the pace and the price:

Diluted shares fell from about 437M to about 396M in six quarters, and about 7% over the last year.
Financing outflows ran about $6.8B over nine months, roughly 9% of market cap annualized.
Retiring stock at a ~9% FCF yield is a high-return use of cash. Adobe did far more expensive buybacks when the stock was in the $500s and $600s.

Lower prices mean each repurchase dollar retires more shares. The market's pessimism makes the buyback cheaper.

4. Pre-empting the bear's best points¶

"Margins are compressing." This is the bear's strongest argument, and I won't dismiss it. Operating margin was 34.8% in Q3, down about 150 bp YoY, and cost of revenue grew 18.8% against 12.9% revenue growth. Three things keep it in perspective: - A 34.8% operating margin is still elite. Q3 operating income rose 5.2% sequentially, and margin recovered from 33.8% in Q2. - The data doesn't say why costs rose. AI compute is a plausible cause, but that's my inference. If so, Adobe is paying the cost of monetizing AI inside its products. That is the opposite of being displaced by it. - Even with the compression, FCF is growing 11%. The cash flow statement is the sturdiest part of the report.

"Net income grew only 3% in Q3." That's true, and the cause below the operating line isn't in the data (it could be tax, interest or other items). But operating income grew 8.3%, operating cash flow grew 14.8%, and FCF is about 128% of net income. I'd want SBC checked, but the cash story isn't weak.

"Cash is down 31% and the current ratio is 0.77." Cash fell because Adobe returned it to shareholders. For a subscription business, current liabilities usually include prepaid deferred revenue, though the tool didn't give me that line and I can't confirm it. With net debt at 0.25x EBITDA and $9B+ of annual FCF, this is not a solvency story.

"The CEO sold $18.3M." It was one sale, at about $244 in April, and it makes up about 94% of the year's insider sales. The other sales total about $1.2M. The same data shows Director Ricks buying $1.95M at $194.51 on June 25, within a few dollars of the 52-week low. He is about 31% in the money. I don't know whether the CEO sale was under a 10b5-1 plan, so I won't over-read it, but I wouldn't over-read it as bearish either.

"Rates: Polymarket has a 78% December hike." That comes from a thin ~$1M market that the macro desk couldn't cross-check, since every FRED call failed. Even if it's right, the logic cuts my way. This is a 14x P/E stock with a 9.4% FCF yield, not a long-duration growth multiple. The recession odds are only 8%, which supports enterprise software demand.

5. The technicals support a bottoming process, though not a breakout yet¶

Higher low: 231.01 on 9/28 versus the June low of 193.41.
The weekly SuperTrend is up, with its stop at 206.08.
MACD histogram is +2.75 after turning positive on 10/8.
RSI is 56, not overbought.
OBV has recovered about 17M from its September low.
Price is above the 200 SMA (252.93) and the 10 EMA (247.16).

The bear will point to ADX at 13, the monthly SuperTrend still down, the daily z-score near +2, and the dense resistance cluster at 255–257. Those are fair points, and a clean close above ~257 would be the confirmation. But low ADX also means the selling pressure has drained away, and ATR is contracting from 10.4 to 8.5. The setup is basing, and the risk can be defined: a 2×ATR stop sits near 237.5, about 7% below the current price.

6. Catalysts¶

Software M&A: Salesforce is paying about $5.7B cash for Braze, a competitor to Adobe's Experience Cloud. ADBE rose about 2% on the news while CRM fell about 2%. Jefferies says it could spark more deals. No headline names Adobe as a target, so this is a valuation signal and not a bid.
AI partnerships: Adobe is deepening AI partnerships across its creative and customer-experience tools. I only have the headline, so I won't claim more than that.
Q4 / FY27 guidance, likely mid-December: If revenue growth holds near 13% and margins stabilize, the "AI loser" label gets much harder to defend at 14x earnings.

7. Where I'm cautious¶

The 10/21 price bar is provisional.
The sentiment data is low quality. Half the bullish StockTwits posts come from one user, and Reddit was disabled. I'm not leaning on it.
Software dispersion is high, and Adobe needs to show AI monetization, not just AI participation.

Bottom line¶

Adobe is growing revenue about 13%, generating roughly 9% of its market cap in free cash flow each year, shrinking its share count about 7% a year, and trading at about 14x earnings. A director bought near the low, and revenue growth is speeding up while the narrative says it should be dying. If the bear believes AI is hollowing out Adobe's franchise, I'd like to see it in the numbers: which line item shows deterioration besides margins, which are still best-in-class? Bull Analyst: # Bull Rebuttal: The Margin Problem Is Real, But It Isn't the Whole Case

Several of your hits land, so I'll concede those first and then show where the argument still favors owning the stock.

What I'm conceding¶

"Accelerating" overstated it. Growth stepped up 0.7 points, then 0.2. The accurate claim is that growth is holding at about 13%, up from about 10.5% a year ago.
Insiders are a wash. The CEO's sale was 9.4x the size of Ricks' purchase, and Ricks' blended cost is only about 6% in the money. I'm dropping insiders from the thesis.
Braze was sector beta. Five software names rose together. M&A is not a pillar of my case.
The $300 used an unchecked input. I address that in section 2.
Net income conversion slipped in all three quarters. It was 78.1/76.5/77.6% against 83.7/80.2/81.5%, so it isn't a blip, and I can't explain it.
Gross margin is the clearest deterioration. Year over year it went +50 bp, +10 bp, then −60 bp.

1. Margins: real, but smaller and less steadily worsening than your table implies¶

Compression narrowed in Q3. Year-over-year operating margin change was about −6 bp in Q1, −209 bp in Q2 and −147 bp in Q3. That is one data point and I won't oversell it, but it is the first narrowing.

The bigger leak is the one that eased. Opex growth went 13.2% → 17.2% → 14.8%, so it peaked in Q2. COGS growth went 6.8% → 12.1% → 18.8% and is still accelerating. You're right that opex was the bigger drag in Q3 (about 90 bp against 60 bp). But the line still getting worse is the smaller one, at about 11% of revenue.

Extrapolation test. Suppose operating margin keeps falling 150 bp a year for three more years (34.8% → 30.3%) while revenue grows 12%. Operating income still rises about 22% cumulatively, roughly 7% a year. It only stops growing if revenue growth also collapses to about 4.5%. If conversion to net income also keeps slipping 4 points a year, net income growth is about +2%, which is roughly where it is today. Extrapolating your trend gives the status quo, not a collapse.

You'll say the real risk is a step change from AI, not extrapolation, and I agree extrapolation doesn't capture that. But a step change would show up in revenue, and revenue is holding at 13%.

Incremental cash margins. You computed a 7% incremental net margin. On cash, 9-month operating cash flow rose $775M and FCF rose $740M on $2.2B of added revenue. That is a 34–35% incremental margin against a 37.8% average. The NI-to-cash gap could be SBC, amortization or working capital, and I can't split them. But the cash line isn't showing the dilution that net income shows.

2. Valuation: use the burdened number¶

You're right that the $300 leaned on pre-SBC FCF. So I'll use your number. GAAP net income of $7.28B on a $99.1B market cap is a 7.3% earnings yield, with every cost counted, on a business growing revenue 13%.

The EPS math at a constant multiple is also yours. Net income +3% and a net share count down about 7% (diluted, so net of SBC issuance) gives EPS growth of about 10%. On TTM EPS of $17.91, that is about $19.70.

12-month scenario (illustrative)	P/E	Price	vs. $254.62
Retest of June-low multiple (~11x on back-solved TTM EPS of ~$17.5)	11x	~$217	−15%
Same, with EPS growth stalling to 5%	11x	~$207	−19%
Multiple holds	14.2x	~$280	+10%
Re-rating (about 22x a year ago, assuming ~10% EPS growth)	17x	~$335	+32%

Each turn of multiple is worth about $20 a share. The downside is real, and I'm not hiding it. But the price is down 46% from the high while EPS rose, so the multiple fell by more than 46%. The bet is that margin stabilization recovers part of that.

3. The buyback "treadmill"¶

It's a smaller draw than last year. Financing outflows were $6.8B this year against $8.5B last year, while FCF rose 11%. That is 91% of FCF now against 126% then. Financing plus investing was 114% of operating cash flow, down from 139%.
Equity is flat over the last twelve months ($11.77B → $11.76B). The 29% decline from the Dec-2023 peak is old news.
Buying at $500–600 was a mistake, and I'll say so. That is sunk cost. The question now is whether buying at $254 and ~14x is the same decision, and it isn't.

4. The balance sheet¶

Your arithmetic helps me here. Current liabilities rose $2.65B, but noncurrent liabilities fell $1.4B. So about half the jump looks like reclassification (debt coming due is my guess, unconfirmed). Total liabilities rose only 7.3%, against revenue up 12.9%.

On cash, "down 31%" runs from February, which looks like a seasonal peak. Year over year it is down 12.5% ($4.98B → $4.36B). The investing outflow of $1.9B is unexplained. If part of it is short-term investment purchases, the tool's cash line overstates the decline. The fundamentals report says short-term investments aren't in the data. If it's acquisitions, that's a negative. I'd check that first, and it's a sizing issue, not a thesis-breaker.

5. "Sold the news"¶

If those volume spikes were earnings (unconfirmed), the market sold three prints in a row, including Q1, when margin was flat at 37.8% and EPS rose 11%. A market that sells good prints is pricing a narrative, not the reports. Narratives get settled by reported numbers, and four quarters of revenue growth haven't confirmed the bearish one. December guidance is the next test.

6. Technicals: conceded, with a plan¶

ADX at 13 means no trend. The selloff's trend ended (ADX peaked at 31.9 on 9/29), but no new uptrend is established. The monthly SuperTrend is down, price sits under dense resistance, and today's bar is provisional. The technical report's base case is a 231–267 range.

So I wouldn't buy it all here:

Now: from $254.62, +15% to the 8/31 close of $292.79 against −9.3% to the 9/28 low of $231.01 is only about 1.6:1.
On a pullback to ~$245 (10 EMA and Bollinger midline), the same target is +19.5% against −5.7% to $231, about 3.4:1.
On confirmation: a close above ~$257 with ADX rising toward 20 and OBV above −198.9M.

I'd scale in on a pullback and size modestly until the December print.

What would change my mind¶

Revenue growth falls below ~11%. Then the margin cost isn't buying anything.
Q4 year-over-year operating margin compression widens beyond Q3's ~150 bp.
Gross margin falls another ~60 bp year over year.
Buybacks become debt-funded, with financing outflows above FCF and rising debt.
A weekly close below $231.

Bottom line¶

You've shown that Adobe's profit conversion is deteriorating, and I agree. But the evidence says it is deteriorating on a stable top line, with the margin hit narrowing in Q3. Even your extrapolation gives roughly today's earnings picture: low single-digit net income growth, about 10% EPS growth, and a 7.3% burdened earnings yield. At 14x that is not a collapse price. The real debate is whether the multiple heads back toward 11x or toward 17x, and that depends on whether margins stabilize. We'll learn that in about seven weeks. Bull Analyst: # Bull Rebuttal: Closing Argument

You've moved me from "buy" to "small starter," and I think that is where the evidence supports. First, what you've won. Then, where I still disagree.

What you've won¶

"Revenue would show it" was wrong, and it contradicted my own round one. With annual contracts, revenue is the last line to crack. Revenue growth is necessary evidence, not sufficient evidence, and the data has no RPO, deferred revenue or net-new ARR to look ahead with.
The tactical reward-to-risk is poor. It's about 0.7:1 from $254.62. Using the 224.67 intraday low instead of the 231 close, a $245 entry risks about 8.3% to make about 8.4%, roughly 1:1. This isn't a trade. It's a valuation position or nothing.
Stops don't survive gaps. 6/12 was −6.8%. Position size has to be the risk control.
Your COGS arithmetic holds. I also get about 120 bp if COGS growth reaches ~25%. It is the line to watch.
The conversion slip is unexplained. It has now slipped three quarters running.

1. Waiting isn't asymmetric¶

You wrote that "a clean print costs you part of the move, a bad one costs you the gap." A clean print also gaps, upward. If gaps are similar in size either way (6/12 was −6.8%), waiting forgoes the up-gap and avoids the down-gap. That is a bet on probabilities, and neither of us has an edge on them. What I can control is size. A 7% gap on a third-size position costs about 2.3% of intended capital.

2. The 11x row isn't the default¶

June's ~11x was set on the Q2 print, the worst margin print in the data (33.8%, −209 bp). Q3 improved on it: −147 bp, with operating income up 5.2% sequentially. To retest 11x, Q4 has to be worse than the print that created it. That is exactly my kill criteria, so it isn't a base case.

You're also right that my table overweighted the downside. Rows 1 and 2 are one scenario with two EPS paths, so equal weights put 50% on a retest. Even then you get about +2%, and expected value only turns negative if more than half the probability sits on that retest. My own judgment weights (30% / 45% / 25%) give about +7%. That is modest, not a screaming buy, and it argues for modest size.

3. The conversion leak is below the operating line¶

Nine-month operating income rose $565M, but only $154M reached net income. Below-the-line costs (operating income minus net income) rose from $1.17B to $1.58B, up 35% against operating income up 8.8%. If it were all tax, that is roughly 4 points of effective tax rate.

This line can't show AI eroding the product, because it sits below operating income. Two candidates are tax and interest/other income. One tax mechanism worth checking is RSUs vesting below grant price after a 46% drop, which would turn windfalls into shortfalls. That is a hypothesis and not in the data. Either way, my 7.3% yield uses reported net income, so the slip is already priced in. If it's temporary, the base is understated.

4. Buybacks and the balance sheet¶

SBC reconciliation. Your SBC estimate of $1.3–2.5B puts FCF-less-SBC at about 6.9–8.1% of market cap. That brackets the 7.3% GAAP yield, so I'm not smuggling the 9.4% back in.
"Buyback slows or cash falls" is a false dichotomy. There's a third path, refinancing. Net debt is about 0.25x EBITDA, and a $1.4B maturity (if that's what it is) is about 15% of a year's FCF.
EPS doesn't collapse to 3% unless the buyback stops. A 15% slower pace cuts the net share reduction from about 7% to about 5.6%, and EPS growth to about 8.8%.
The investing outflow may cut against me. From memory, not the data, Adobe announced a ~$1.9B Semrush acquisition in late 2025. If it closed in FY26, it would explain part of the outflow and add acquired cost and amortization. It would also mean some of the 12.9% isn't organic. That is one more reason "accelerating" is retired, and it needs checking in the 10-Q.

5. Neither of us can read the tape¶

The stock rose 51% from June 25 to August 31 ($193 to $293), fell 21% to September 28, then rose 10%. Our data has no Adobe-specific headline for any leg. By your corrected figures it fell 9% before the likely Q3 print window (292.79 to 266.51), was flat through it, then fell another 13%. "The market is pricing conversion, three for three" is as unprovable as my "narrative" line. I'll drop mine if you drop yours, and valuation stays as the anchor.

What we agree on, and the plan¶

I adopt your test: Q4 gross margin down ≤ ~30 bp YoY, an FY27 guide implying flat-to-up operating margin, conversion explained, and nothing ugly in the 10-Q. The remaining disagreement is whether to hold a small position through the print.

Read the 10-Q first. You're right that sizing before reading it was backwards. I need the tax note, SBC, the composition of current liabilities, and the investing outflows. The tools didn't surface them, and I can't read the filing here. Anything ugly means standing down.
Starter of at most a third of intended size, ideally on a pullback to the 10 EMA/Bollinger midline ($241–247). Size it for a gap, not a stop.
Add after the print if the criteria above are met, or on a close above ~$257 with ADX rising toward 20 and OBV above −198.9M.
Exit if revenue growth falls below ~11%, Q4 operating-margin compression widens beyond ~150 bp YoY, or there's a weekly close below $231.

Bottom line¶

At a 7.3% GAAP earnings yield with about 10% EPS growth at a constant multiple, ADBE doesn't need a re-rating to work. It needs the margin hit to stop widening. Q3 is one data point on that, a better one than Q2 but not a trend. The gating items are in a filing I haven't read and a print seven weeks away, so the position should be small. You'd rather pay a higher price for certainty, and that is a legitimate choice. Mine is to pay a third now for exposure, given symmetric gaps and a valuation that already reflects the worst print in the data. Call it wait-and-see if you like. The difference between us is about a third of a position. Bull Analyst: # Bull Closing: What's Left Is One Filing and a Third of a Position

You've narrowed the disagreement better than I did. I'll concede what you've earned, push back on three points, and then state what I'd do.

What I'm conceding¶

My position today is zero. My sequence is to read the 10-Q first, and I can't read it here. The thesis is conditional until I do.
Q3's improvement came from opex, not gross margin. Your decomposition is right: the implied opex drag went from about −219 bp to −87 bp, while gross margin went from +10 bp to −60 bp YoY. COGS growth of +18.8% is the line to watch.
The revenue test has to be organic. If Semrush consolidated and added 1–1.5 points (your estimate and my memory, neither in the data), Q3 organic growth is about 11.4–11.9%. That is above FY25's ~10.7% but below Q1's 12.0%. The accurate claim is "steady, modestly above last year," not "accelerating." The 10-Q's acquisition note will settle it.
I never wrote a mixed-print branch. It's below.
Every heavy-volume window you listed was flat or down. I'll explain below why I don't read much into that.

1. "A multiple it hasn't paid in a year" is wrong¶

The 8/31 close was 292.79. Against TTM EPS of about $17.47 at the time (back-solved), that is ~16.8x. Against today's $17.91 it is ~16.4x. That was seven weeks ago, and the 6/25 low was ~11x. So the multiple went 11x → ~16.5x → 14.2x in about 16 weeks.

That doesn't make a re-rating likely, and I'll mark my table down. Swap the 17x row for 16x (~$315, +24%) and my 30/45/25 weights give about +5%, not +7%. Your breakeven of roughly 45% on the retest and ≤10% on the re-rate is the real test. I don't think the evidence supports that split, but it doesn't prove my weights either. They are judgment. Whether +5% clears the hurdle for a 1.4-beta stock is a portfolio question, and neither of us can settle it without the 10-year yield.

2. The print-window tape is a downtrend sample¶

The stock fell about 29% over this window, from 359.91 to 254.62. In that kind of tape, waiting beats buying almost anywhere, print or not. The largest up-moves in our data (10/15 +4.6%, 10/20 +3.9%, and the +51% run from 6/25 to 8/31) don't coincide with a print, as far as the data shows. So gaps happen away from prints too. I'll drop the claim that the gap is symmetric. Neither of us has an edge on its direction, and that is why position size is the control.

3. The mixed-print branch¶

Q4 print outcome	Action on a ≤⅓ starter
Clean: organic revenue ≥ ~11%, GM down ≤ ~30 bp YoY, FY27 guide flat-to-up operating margin, conversion explained	Add toward full size
Mixed: e.g. revenue ~12%, GM −30 to −60 bp, ambiguous guide	Hold the starter, don't add, wait for call and 10-K detail
Bad: organic revenue < ~11%, YoY operating margin compression > ~150 bp, GM worse than −60 bp, a guide implying margin decline, or buybacks funded by debt	Exit

The conjunction to add and the disjunction to exit are deliberate. The plan is asymmetric in the conservative direction. A mixed print leaves me holding a small position and committing nothing more.

4. A testable reconciliation on the conversion slip¶

This is a hypothesis, not a finding. Over nine months, operating income less net income was $1.17B last year, or 18.2% of operating income. If that ratio had held, this year's figure would be about $1.27B. It was $1.58B, an excess of about $310M. Over the same period, OCF minus net income widened from $1.60B to $2.22B, about $620M.

If the excess is a book-only tax shortfall on RSUs vesting below grant price, as I speculated earlier, net income would fall while operating cash flow would not. That is the pattern in the data. A cash interest or cash tax cost would have dragged OCF down with it. Working capital, including the $2.65B jump in current liabilities, could also be inflating OCF, so this is compatible with the data and not proven.

I accept your point that the drag persists while the stock trades below grant prices. The 10-Q can confirm or kill this directly through the tax provision and effective rate, any stock-comp tax shortfall, cash taxes paid, and SBC expense. If cash taxes are the driver, my story is wrong and I'll say so.

5. Where the two of us actually stand¶

We now share almost the same checklist: the 10-Q gating items, organic growth, Q4 gross margin, the FY27 margin guide, conversion, and a close above ~257 with ADX rising and OBV above −198.9M. Your remaining objection is that holding a third through the print is a lottery ticket. The same ~2.3% of intended capital I'd lose on a −6.8% gap is what you'd forgo on a +6.8% gap. Given that neither of us can predict the gap's direction, the difference between us is a coin flip over a small amount.

Final bull position¶

Valuation: 14.2x GAAP, a 7.3% burdened earnings yield, and about 10% EPS growth at a constant multiple while the buyback continues. The stock has traded between ~11x and ~16.5x in the last 16 weeks, so the multiple is volatile and the position should be small.
What the bull case needs: the margin hit to stop widening. Q3 is one better data point on that, not a trend.
Today: zero until the 10-Q gating items are read. Anything ugly means standing down.
If clean: a starter of at most one third of intended size, ideally on a pullback to $241–247 (10 EMA and Bollinger midline). Size it for a gap, since stops won't hold.
Add on a clean Q4 print per the table, or on a close above ~257 with ADX rising toward 20 and OBV above −198.9M.
Exit per the table, or on a weekly close below $231.

The bear is right that certainty has a price and that the next seven weeks decide most of this. My view is that a 14x multiple on stable, cash-backed earnings already prices a good deal of caution. That justifies a small, staged position once the filing is clean, but not a conviction buy today. Bull Analyst: # Bull Close: The Price Is the Lever

We agree on the action: zero today, at most a third after a clean 10-Q, and adds only after the print. Your last round was about the odds. Two of your points, the hurdle and the thresholds, are answered by arithmetic from our own tables, so I'll concede what you've earned and then show that.

What I'm conceding¶

The RSU mechanism is withdrawn. You're right that a vest below grant price shrinks the deduction. Cash taxes rise by the same amount tax expense does, so net income and operating cash flow fall together. It can't explain a widening OCF-minus-NI gap. If it is behind the conversion slip, the slip is a real cash cost that lasts while vests sit below grants. I also drop "if it's temporary, the base is understated." That was circular.
"14x already prices caution" has no anchor. The multiple went 11.1x → 16.8x → 12.9x → 14.2x in sixteen weeks, so 14x is just the middle of the range.
At $254.62, my weights give +5.4%, below a CAPM-style hurdle. I don't have the risk-free rate either. With any plausible rate, the hurdle is roughly 9–11%.
Semrush is the most valuable fact in the filing. I raised it, but only from memory. The $1.7B of non-capex investing outflow is roughly the right size for a ~$1.9B deal net of acquired cash, which raises my odds that it closed inside the window.
Your guide condition is accepted. The FY27 guide has to pair the margin outlook with an organic revenue outlook of ~11% or better.

1. What each path earns at a constant multiple¶

Nine-month net income growth splits cleanly into three factors, using the reported figures:

Revenue +12.5% × operating margin (−3.3%) × NI/operating-income conversion (−5.3%) = NI +2.9%

Net income grows 3% against 13% revenue growth because of two drags of similar size. Holding revenue at +12% and share count at −7%, which you've accepted survives a slower buyback at ~9% EPS growth, here is what each path earns at today's 14.2x:

Path (illustrative)	NI growth	EPS growth	Price at 14.2x
Both drags continue (my "hold" row)	~+2.5%	~+10%	~$280
Margin stabilizes, conversion keeps slipping	~+6%	~+14%	~$290
Conversion stabilizes, margin keeps compressing	~+8%	~+16%	~$295
Both stabilize	~+12%	~+20%	~$305
Revenue slows to 10%, both drags continue	~+0.6%	~+8%	~$275

Two things follow. First, my base case is persistence, not a turn. The "hold" row already assumes Q3-like compression continues, and a turn is upside. Second, every earnings path is positive at a constant multiple. The downside comes from the multiple, and at persistence the stock loses money a year out only below ~12.9x. That is where it traded on 9/28, so it isn't remote, but it is the low end of the range. The $300 I withdrew earlier comes back as the all-stabilize case. It is not the base case.

2. Your hurdle argument is answered by the entry price¶

The scenario prices don't depend on what I pay. Holding my 30/45/25 weights and the three row prices (~$212 retest, $280 hold, $315 at 16x) fixed:

Entry	Retest	Hold	16x	EV
$254.62	−17%	+10%	+24%	+5.4%
$247	−14%	+13%	+28%	+8.6%
$244	−13%	+15%	+29%	+10.1%
$241	−12%	+16%	+31%	+11.4%

At $254 I agree it doesn't clear the hurdle, and I wouldn't buy there. At $241–247 the same weights reach roughly the hurdle. That is why the plan says pullback and not market order. You'd rather pay more after the print. Fair, but a clean print takes the retest weight down and the price up, and the two roughly offset. The weights are still judgment, and each 10 points moved from the 16x row to the retest costs about 4 points of EV. I'm not re-weighting to rescue the number.

3. The thresholds¶

You say a Q4 that repeats Q3 "lands on my exit lines." Check the lines. −60 bp is not worse than −60 bp, and −147 bp is not more than 150 bp. A Q3 repeat lands in my mixed row, which means hold the starter and don't add. That is by design, and it is the +10% row. But you're right that exit lines a few basis points from Q3 would trigger on rounding noise, so I'll add a ±15 bp tolerance. Inside it the outcome is "mixed" and the guide decides. If the company doesn't break out the acquisition contribution, your organic-revenue condition is unresolved, which means mixed and no add.

4. Semrush: I'll set a stricter gate than yours¶

If the 10-Q shows Q3 organic growth near 11.1%, down from Q1's 12.0% (with Q1's acquisition exposure unknown), I'll treat that as a fail. Eleven percent was my floor for "the margin cost is buying something." A floor you're sliding toward is not a pass. The thesis is margin stabilization on a steady top line, and a decelerating top line fails it. It would also change my diagnosis of the gross margin drift. Lower-margin acquired revenue is a different cause from AI compute. It would be more benign for the product thesis and worse for earnings quality, as you said.

The plan¶

Today: zero.
After the 10-Q: a starter of at most one third at $241–247, only if all of these hold:
Organic growth is not decelerating toward 11%.
The tax note and SBC explain the conversion slip.
Current liabilities and investing outflows are benign.
No buying at $254+, where EV is ~+5%.
Add if Q4 is clean, with gross margin down ≤ ~30 bp YoY and a guide pairing margin with organic revenue. Or add on a close above ~257 with ADX rising toward 20 and OBV above −198.9M.
Exit on a bad print, meaning organic growth under ~11%, operating-margin compression beyond ~150 bp, gross margin worse than ~−60 bp, or debt-funded buybacks. Also exit on a weekly close below $231. Size for a gap, since stops won't hold.

Bottom line¶

We agree on the action and differ on the odds. At a constant multiple, ADBE earns roughly its cost of equity if the margin and conversion drags merely persist. It earns more if either stops, and it loses only if the multiple falls to the low end of its 16-week range. That makes it a stock to buy on price discipline at $241–247, not on conviction at $254. You may be right that the retest odds are higher than my 30%. The 10-Q and the December print will test that, and I'd read the filing before I put on any position.

Bear Researcher¶

Bear Analyst: # Bear Case for ADBE: Cheap for a Reason

You're right about several things. Revenue is growing about 13%, the cash generation is real, and nobody serious is arguing solvency. Our disagreement is over what those facts are worth, and your closing question frames it well.

1. "Which line item besides margins?" Margins are the thesis¶

At an 89% gross margin and 35% operating margin, margin durability is what you're paying for. A business like this is valued on how much of each new revenue dollar survives. Here is the nine-month picture from the fundamentals data:

9 months, FY26 vs FY25	Growth
Revenue	+12.5%
Operating income	+8.8%
Net income	+2.9%
Diluted EPS	+9.9%

Adobe added $2.2B of revenue and only $154M of net income. That is a 7% incremental net margin, and the incremental operating margin is about 26%, against a roughly 36% average. Growth is being bought at a steep discount.

Your answer to the net income gap was that the cause below the operating line "isn't in the data." That doesn't resolve it. Net income converted from operating income at 78.1%, 76.5% and 77.6% in Q1–Q3, against 83.7%, 80.2% and 81.5% a year earlier. It slipped about four points in all three quarters, so this is not a one-quarter blip. And net income is the denominator of your 14x P/E.

You also argued that rising cost of revenue (+6.8% → +12.1% → +18.8%) means Adobe is "paying the cost of monetizing AI." If rising costs prove strength, what would prove weakness? Gross margin has fallen three quarters in a row (89.6% → 89.2% → 88.7%). Opex growth of 13–17% is a bigger leak than COGS. A franchise defending itself would look exactly like this, spending more on compute, R&D and go-to-market to hold growth near 13%. I can't prove that interpretation, but your reading is also an inference.

2. The stock fell 46% while revenue accelerated¶

The close went from 359.91 to 193.41, down 46%, while growth moved from 10.7% to 12.9%. Your best evidence was visible the whole way down, and the market ignored it. That tells you the market is pricing terminal margins and AI exposure, not this year's top line. "The burden of proof has shifted" is a rhetorical claim, not a pricing one.

The acceleration is also flattening. Growth stepped up 0.7 points, then 0.2. Q3 sequential growth was 2.1% against 2.0% a year earlier.

The heaviest volume days of the year also line up with what look like earnings windows. I can't confirm the dates. The biggest was 25M shares on 6/12, after the quarter where operating margin hit its 33.8% low. There was another gap-down on 17.4M shares on 3/13. After the 9/10–9/11 volume spike, the stock fell from 292.79 (8/31) to 231.01 (9/28), down 21%. If those were prints, the market has repeatedly sold the news.

3. Your $300 depends on which earnings you capitalize¶

Your $300 is $9.35B of FCF at an 8% yield. Apply the same 8% to GAAP net income of $7.28B and you get about $234, roughly 8% below today's price.

I'm not saying GAAP is the right base. Amortization of acquired intangibles is a legitimate add-back. But SBC isn't, and you wrote "I'd want SBC checked" and then built the target on the unchecked number. The $2B gap between FCF and net income is unexplained, and the favorable reading is the one carrying your valuation.

4. Buybacks are a treadmill funded by the balance sheet¶

Net income grew 3% and EPS grew 10%, so the buyback is doing most of the work. You noted that Adobe bought stock in the $500s and $600s. Doesn't that concede that a lot of this capital was destroyed? Equity is down 29% from its December 2023 peak, so ROE of 61.9% is an artifact.

Financing outflows ($6.8B) plus investing outflows ($1.9B) came to $8.7B against $7.6B of operating cash flow, or 114%. Capex is only $180M, so about $1.7B of investing outflow is something else. It could be short-term investment purchases, which would be benign, or acquisitions, which would not. Neither of us knows, and it nearly doubled year over year.

If margins keep slipping and FCF growth slows, the buyback shrinks and EPS growth falls toward net income growth of 3%. That is the 14x P/E re-rating risk.

5. The balance sheet is not "sturdy," even if it isn't a solvency story¶

I agree it's not a solvency story. Still:

Current liabilities rose $2.65B (+29%) in a year, while total liabilities rose only $1.23B. Noncurrent liabilities fell about $1.4B (−18%), which is consistent with debt moving into current. I can't confirm that.
Working capital swung from +$0.17B to −$2.7B, and cash is down 31% since February.
You called the cash flow statement the sturdiest part of the report. But you couldn't explain what is in current liabilities. If part of that $2.65B is accrued items and not deferred revenue, it flatters operating cash flow. A $2.65B balance sheet jump that nobody can decompose undercuts that confidence.

6. You're reading insider activity asymmetrically¶

You wouldn't over-read the CEO's $18.3M sale, but your bottom line leans on a director's $1.95M purchase. The CEO's sale was 9.4 times larger. Ricks also bought 2,250 shares at $443.98 in January 2025, and his blended cost of about $240 is only about 6% in the money. His buying hasn't been a reliable timing signal. Across 12 months and a 48% peak-to-trough drawdown, no executive bought a share.

7. The technicals describe a range, not a base¶

Low ADX isn't exhausted selling. ADX at 13 means no trend in either direction. The bounce from 231 happened while ADX dropped to 9.49, so there is no strength behind it.
Defined risk is thinner than you suggest. Price is pinned between the 200 SMA (252.93) and the 50 SMA (255.67). The daily SuperTrend is down (stop 256.93), and so is the monthly (stop 401.26, 36.55% above). The weekly stop you cited is 23.55% away.
The bounce is already extended. Today's high was 257.63 and the close was 254.62, below yesterday's 256.73. The daily z-score is +1.95, and the structure is a lower high (292.79 vs 359.91).
Reward-to-risk is unfavorable. The nearest overhead levels (265.60 and 266.51) are +4.3–4.7% away, while your own 2×ATR stop (237.56) is −6.7%. September buyers between 266 and 293 are all underwater, so overhead supply is real.

8. Catalysts and rates¶

The Braze deal moved the whole group. monday.com, DocuSign, Intuit and MongoDB were up too, so that was beta, not an Adobe re-rating. Salesforce fell 2% as the acquirer. And $5.7B is about 6% of Adobe's market cap, so Braze says little about a take-out for a $99B company. As you noted, nothing names Adobe as a target.

December guidance needs two things from your own wording: growth near 13% and stabilizing margins. The market has already shown it punishes margin disappointments despite strong revenue.

On rates, I'll accept your point that the 78% hike odds sit in a thin market. But the 97% "no cuts in 2026" market is about $9M deep. That means no rate relief for a stock with a beta of 1.4. I also can't compare the earnings yield to the 10-year because the FRED calls failed, and that is a gap on both sides.

What would change my mind¶

Show me gross margin stabilizing for two straight quarters, net income growth converging toward revenue growth, and a breakdown of current liabilities and investing outflows. A clean close above ~257 with ADX rising toward 20 and OBV above −198.9M would also change my read. None of that is in the data today.

Bottom line¶

Adobe is a high-quality franchise whose reported growth is converting to profit at a falling rate. It trades at 14x earnings that are growing about 3%, the per-share growth comes from buybacks that consume essentially all free cash flow, and it sits in a trendless range directly under resistance. The market already sold Adobe down 46% during a period of accelerating revenue. Your own question points to the answer: the margin trend is the case, and it hasn't turned yet. Bear Analyst: # Bear Rebuttal: Your Plan Is Wait-and-See, and So Is Mine

You've conceded a lot, and your revised case is more defensible than your opening. Here is what I'll give you first.

What I'm conceding¶

Q3 compression narrowed from Q2 (−209 bp to −147 bp). That is real, though it is one data point after a −6 bp Q1.
The 7.3% GAAP earnings yield is the right base. I'll argue from it.
Cash is down 12.5% YoY, not 31%. The February peak was a fair thing to challenge.
Financing outflows fell to 91% of FCF from 126%.
A correction of my own. I tied the slide to the 9/10–9/11 volume spike. The 9/4 close was 266.51 and the 9/14 close was 265.60, so the stock was roughly flat across those days. The 13% slide to 231.01 came in the two weeks after. I use the corrected version below.

1. Four of your five exit triggers can only be tested on one date¶

Your "change my mind" trigger	When you can observe it
Revenue growth < ~11%	December print
Q4 YoY operating-margin compression > ~150 bp	December print
Gross margin down another ~60 bp YoY	December print
Buybacks become debt-funded	December print / 10-K
Weekly close < $231	Anytime

You propose to hold through the event that decides whether you're wrong. Your "defined risk" also doesn't survive a gap. On 6/12 the stock closed at 204.02 against 218.80 the day before, down 6.8% on 25M shares, about twice the 3.35% ATR. A 2×ATR stop (237.56) or a 231 weekly-close rule only works if the market trades through those levels. The print date, Dec 9, comes from a StockTwits user and isn't confirmed.

Waiting is asymmetric. A clean print costs you part of the move. A bad one costs you the gap. Before the print you're paying for the right to be early, with no information edge.

2. "A step change would show up in revenue" contradicts your opening¶

Round one said: "I'll concede that revenue can lag the damage." Now you say revenue would show it. Both can't hold. With annual and multi-year contracts, erosion enters at renewal and recognition spreads it over the following year, so revenue is the last line to crack. The lines that are moving now are COGS (+6.8% → +12.1% → +18.8%) and gross margin (+50 → +10 → −60 bp YoY).

Your extrapolation test also assumes the wrong shape. A steady −150 bp a year is linear, but COGS growth is accelerating by 5–7 points a quarter. One more quarter at that pace puts COGS growth near 25%. On 12–13% revenue growth, that costs roughly 120 bp of gross margin YoY, double Q3's 60 bp. This is illustrative, not a forecast.

The extrapolation also treats 12% growth and −150 bp of margin as independent. If the spending is what holds growth near 13%, then 12% growth at −150 bp is the good branch.

3. The cash line is less comforting than "34% incremental" suggests¶

FCF margin slipped too: 38.3% → 37.8% over nine months. The dilution is there, just smaller.
Cash is outrunning profit. Your 34–35% incremental cash margin exceeds the 26% incremental operating margin. OCF minus net income was $1.60B in the first nine months of last year and $2.22B this year, up 39% against revenue up 12.5%. The candidates are amortization (a fair add-back), SBC (a real cost) and working capital (the $2.65B jump in current liabilities, which doesn't repeat). Only one of those three is free cash.
The share-count math points to SBC. Nine months of financing outflows of $6.8B annualize to about $9.1B, or 9.2% of market cap. Diluted shares fell about 6.7–7%. Even if the average purchase price was ~10% above today's, that leaves roughly 1.3–2.5 points of buyback that only neutralizes issuance. That is $1.3–2.5B a year, the same size as the $2.1B gap between FCF and net income.

This is my inference, not a reported figure, and the outflows may include debt repayment or RSU tax withholding. But it reconciles the numbers, and it is why I accept your 7.3% over the 9.4% FCF yield.

4. At 7.3%, what are you underwriting?¶

If the multiple holds, the return is about 10% (net income +3%, shares −7%). That is your middle row.

Equal-weighting your four rows (−15%, −19%, +10%, +32%) gives about +2%.
To reach ~10% expected return, with 30% on "multiple holds," you need roughly 40% odds on the 17x row and 30% on 11x.
Every row depends on the margin path, which is the one variable neither of us can see until December.
The FRED calls failed, so we can't compare 7.3% to the 10-year. The one deep rates market, 97% no cuts in 2026 at about $9M, doesn't point to relief. Beta is 1.4.

5. "Sold the print" cuts against you¶

The market sold the Q1 print (flat 37.8% margin, EPS +11%). The next quarter delivered −209 bp of compression and the heaviest volume day of the year. That is what pricing the forward path looks like. After Q3, with revenue +12.9% and margin recovering, the stock still fell 13% in two weeks.

So revenue isn't what the market is pricing. It is pricing profit conversion, and that has worsened in all three quarters: net income as a share of operating income was down 5.6, 3.7 and 3.9 points YoY. The bear prediction is three for three. "Four quarters of revenue growth" is the wrong scoreboard.

6. The balance sheet, taking your guess seriously¶

If the reclassification is debt, about $1.4B comes due within 12 months, competing with a ~$9B-a-year buyback pace. Cash fell $560M in Q3 despite roughly $2.5B of operating cash flow, so Q3 uses were about $3.1B, above the nine-month average of $2.9B. Either the buyback slows, which pulls EPS growth toward ~3% net income growth, or cash keeps falling.

Then there is the list of things you can't explain: - the net income conversion slip - the SBC level - the $2.65B in current liabilities - the $1.7B of non-capex investing outflow, up from $0.9B

Some of these resolve benignly. But the Q3 10-Q is already filed and answers most of them now, and you've proposed sizing before reading it.

7. Your reward-to-risk depends on the full retrace¶

The 1.6:1 and 3.4:1 figures both target 292.79. That path runs through 265–267 and the September cohort underwater between 266 and 293. StockTwits holders say they'd exit near 285–300, though that source is low quality. Targeting first resistance instead:

Entry	Target (265.60–266.51)	Risk	R:R
254.62	+4.3–4.7%	−6.7% (2×ATR)	~0.7:1
~245	+8.4–8.8%	−5.7% (to 231)	~1.5:1

The 231 level is a closing low. The intraday low that day was 224.67.

What would change my mind¶

Q4 gross margin down no more than ~30 bp YoY, with an FY27 guide implying flat-to-up operating margin
Net income conversion back near 80%, or a clear explanation of the slip
The 10-Q showing SBC, the composition of current liabilities and the investing outflows, with nothing ugly in them
A close above ~257 with ADX rising toward 20 and OBV above −198.9M

Bottom line¶

You've gone from "buy" to "scale in on a pullback and size modestly until the print." That is wait-and-see. We now differ only on whether to hold risk through a binary event that answers four of your five kill criteria. Reported growth is converting to profit at a falling rate, the EPS growth depends on ~$9B a year of spending while cash falls, and the stock sits under a dense resistance cluster. I'd rather pay a higher price after the print than own ADBE before it. Bear Analyst: # Bear Final Rebuttal: A Third of a Position Is a Ticket to the Print

You made this closing argument better than your opening, and we now agree on most of the facts. I'll concede what's earned, then show where the remaining gap sits.

What I'm conceding¶

Waiting has a cost. A clean print gaps up too, and on a third-size position that's about 2.3% of intended capital. I accept that.
EPS doesn't collapse to ~3% unless the buyback stops. Issuance is fixed, so the net share reduction falls faster than the gross pace, but your ~9% EPS figure at a 15% slower pace is about right.
Refinancing is a third path. My "slows or cash falls" framing was too binary.
The SBC bracket holds. FCF less $1.3–2.5B of SBC is 6.9–8.1% of market cap, which brackets the 7.3% GAAP yield. I accept 7.3% as the base.
Q3 was better than Q2 at the operating line. Margin compression was −147 bp against −209 bp. Operating income rose 5.2% sequentially against 3.0% a year earlier (2,173 vs 2,109).
The tape truce. I withdraw "the market is pricing conversion, three for three" as a claim about what traders were thinking. The conversion trend itself comes from the filed statements, not from price action.

1. By your own sequencing, your position today is zero¶

Your step one is to read the 10-Q, and you say you can't read it here. Your own rule is "anything ugly means standing down." The gating items (tax note, SBC, current liabilities, investing outflows) are unread, so today you own nothing, which is my position.

The live disagreement is narrower than "a third of a position." It's whether to buy a third after a clean 10-Q and before the print.

The sizing math cuts both ways. If a third-size position moves about ±2.3% of capital on a gap, it can't add much to returns either. The other two-thirds are bought after the print in both plans, so the starter amounts to a lottery ticket on the print.

2. The gap isn't obviously symmetric, and your plan has no mixed-print branch¶

The heavy-volume windows in our data show: - 3/13: gap down on 17.4M shares. - 6/12: −6.8% on 25M shares. - 9/10–9/11: price roughly flat through the window (266.51 → 265.60). - 12/11: 10.2M shares, direction not in what I have.

I see no confirmed up-gap. That is three or four observations and I can't confirm they were prints, so it isn't an edge. It does lean against assuming symmetry.

The structure of your plan matters more. Your add test is a conjunction of four conditions: gross margin down ≤30 bp, a flat-to-up margin guide, conversion explained and a clean 10-Q. Your exit test is a disjunction of three. The likeliest outcome is mixed, for example revenue +12.5%, gross margin −55 bp and an ambiguous guide. In that case you hold a third through a print that settled nothing.

3. "The worst print is already in the price" is wrong on the numbers¶

The June trough was about 11x and the stock now trades at 14.2x, 31.7% above the 6/25 close. In your table, going from 11x to 17x is six turns, and ADBE has covered about 3.2 of them. It did that on one better quarter, with net income growth still around 3%.

The improvement in Q3 also came from the wrong line. Decomposing the year-over-year operating margin change:

	Q2 FY26	Q3 FY26
Operating margin YoY	−209 bp	−147 bp
Gross margin YoY	+10 bp	−60 bp
Implied opex drag	~−219 bp	~−87 bp

The discretionary line (opex) eased by about 130 bp. The structural line (gross margin) worsened by about 70 bp, and cost of revenue growth is still accelerating, at +18.8%.

A retest of 11x doesn't need Q4 to be worse than Q2 on the margin line. It needs an FY27 guide that says margins keep sliding.

4. Your probability table is knife-edge on a variable neither of us can see¶

The weights are retest / hold / re-rate, using your rows (−17% as the average of the two retest paths, +10%, +32%):

Weights	Expected 12-month return
30 / 45 / 25 (yours)	~+7%
40 / 45 / 15	~+2–3%
45 / 45 / 10	~0%

Each 10 points of probability moved from "17x" to "11x" costs about 4.7 points of expected return. The 25% on 17x is also the least supported number in the table. It asks the market to pay 17x for earnings growing ~3% with a three-quarter-old unexplained conversion slip, a multiple it hasn't paid in a year.

For a 1.4-beta stock with no 10-year yield to compare against (the FRED calls failed), +7% may not clear the hurdle. I can't prove that, but neither can you disprove it.

5. Your tax hypothesis makes the slip persistent¶

You suggested RSUs vesting below grant price could be raising the tax rate. That's plausible, but it's a hypothesis and not in the data. Tranches granted at $400–600 keep vesting for years.

If that's the mechanism, the drag lasts as long as the stock stays below those grant prices. "If it's temporary, the base is understated" then becomes "if the stock re-rates, the base is understated," which is circular. It would also be another place where SBC shows up as a real cost. I never said the slip reflects AI erosion, only that it lowers the earnings base under your 7.3%.

6. Follow the Semrush memory to its end¶

You raised the ~$1.9B Semrush deal from memory, and I'll take it seriously on the same basis (not in our data).

It fits the cash flow. Non-capex investing outflows were about $1.7B against $0.9B a year earlier.
It may flatter the 12.9%. From memory, the target had roughly $0.4B of annual revenue, so on the order of 1–1.5 points of quarterly growth if it was consolidated. Organic growth may be closer to your 11% kill line than the headline suggests.
Your first exit trigger needs rewriting as organic growth. None of our tools can compute that number, so the 10-Q is the only source.
It could explain some margin drift. Lower-margin acquired revenue and intangible amortization could account for part of the COGS and operating margin movement. That would be benign for the AI thesis but not for earnings quality. You can't value ADBE on "growth near 13%" if part of it was purchased, and the $1.9B comes on top of a ~$9B-a-year buyback pace.

What would change my mind¶

The 10-Q shows the tax note, SBC, current liabilities and investing outflows, with nothing ugly in them.
It shows organic revenue growth at or above ~11%.
Q4 gross margin is down no more than ~30 bp YoY, with an FY27 guide implying flat-to-up operating margin.
Net income conversion is back near 80%, or the slip is explained and non-recurring.
A close above ~257 with ADX rising toward 20 and OBV above −198.9M.

Bottom line¶

We agree on a lot: 7.3% is the right base, EPS growth at a constant multiple is about 10%, expected value is modest, the gating items are unread, and size should be small.

What's left is whether to hold a third through a binary event. My case against it is that: 1. ADBE has already re-rated about 30% off the worst print. 2. The line that improved is discretionary and the structural lines worsened. 3. Your expected return goes to zero with a 15-point probability shift. 4. Your revenue kill criterion may be reading purchased growth.

My caution costs about 2.3% of intended capital if the print is clean. I'd pay that to see the 10-Q, the guide and the organic growth number first. If the 10-Q is clean and the stock pulls back to $241–247 before the print, I'd be a much smaller bear, but that conversation belongs after the filing is read, not before. Bear Analyst: # Bear Closing: We Agree on the Action, Not on the Odds

Your closing is more honest than most bull cases. Today your position is zero, the starter comes only after a clean 10-Q, and it is capped at a third. That is close to what I said I'd accept. What's left is whether the numbers justify even that.

What I'm conceding¶

"A multiple it hasn't paid in a year" was wrong. On the back-solved TTM EPS of $17.47, the 8/31 close of $292.79 was 16.8x. I retract the claim.
The print-window tape proves nothing. It's a 29% downtrend sample. I drop "no confirmed up-gap" as evidence of asymmetry.
The starter is a coin flip over a small amount. I'll stop arguing about its size.
The mixed-print table fixes my "no branch" objection.
The slip isn't shown to be AI erosion. It sits below the operating line, and I never proved it was.

1. The 16.8x row cuts against you¶

Date	Close	TTM EPS (back-solved)	P/E
6/25	193.41	17.47	11.1x
8/31	292.79	17.47	16.8x
9/4	266.51	17.47	15.3x
9/28	231.01	17.91	12.9x
10/21	254.62	17.91	14.2x

On the same EPS base, the multiple went from 11x to 16.8x in ten weeks. It gave back about four turns in the next four. The multiple in this data is set by sentiment, so "14x already prices caution" has no anchor. I accept 16x as a possible row. But 16.8x was seen once and didn't hold, and the only new fundamental data since is Q3, a report you describe as better than Q2 but not a trend.

2. Your own expected value doesn't clear a hurdle¶

Your weights of 30/45/25 on −17%, +10% and +24% give +5.4%, with a standard deviation near 16%. ADBE has a beta of 1.415. With an assumed equity risk premium of 4–5%, beta alone requires 5.7–7.1% before adding any risk-free rate. The FRED calls failed, so I don't have the 10-year. But a market pricing a December hike (thin, but that's what we have) isn't one where cash pays nothing. You called this "a portfolio question." Under simple CAPM arithmetic it isn't close, and it relies on weights you call judgment.

3. Your thresholds sit at Q3's levels¶

Your exit line for gross margin is "worse than −60 bp." Q3 was −60 bp.
Your exit line for operating margin is ">150 bp." Q3 was −147 bp.
"Clean" needs gross margin at −30 bp or better, a 30 bp improvement from Q3.

So a Q4 that merely repeats Q3 lands on your exit lines. The thesis that "the margin hit stops widening" needs a turn, not persistence. Cost-of-revenue growth has gone +6.8% → +12.1% → +18.8%, and the trend points through the line.

The guide test is also gameable. You conceded that Q3's improvement came from opex, the discretionary line. Management can meet a "flat-to-up operating margin" guide by trimming the same line. That line is probably what's holding growth near 13%. I'd add a condition: the FY27 guide must pair the margin outlook with an organic revenue outlook of about 11% or better. A guide that holds margin by slowing growth isn't clean.

4. The RSU mechanism doesn't do what you need¶

You offered a vest-price tax shortfall as a "book-only" explanation, because net income would fall while operating cash flow wouldn't. As I understand the mechanics, it's not book-only. A vest price below the grant price means a smaller actual tax deduction, which means higher cash taxes. A shortfall would pull OCF down with net income, leaving OCF minus net income unchanged. That gap widened by about $620M (+39%) against revenue up 12.5%.

So the widening has to come from something else: SBC, amortization or working capital. Only amortization is a clean add-back. If the shortfall hypothesis is true, it is a real, persistent cash cost, as you accepted. The tax note and cash taxes paid in the 10-Q will settle this.

5. The revenue exit test may already be failing¶

Both of us are working from memory here, not data, and I could be wrong on the details. I recall Semrush at roughly $100–110M of quarterly revenue, which is about 1.8 points of Adobe's $5.99B Q3 FY25 base. My earlier 1–1.5 point range assumed a partial quarter. If the deal closed in H1 FY26, Q3 would carry a full quarter. Organic growth would then be near 11.1%, down from Q1's 12.0%, right on your 11% line. If the deal hasn't closed, the problem disappears. That makes it the highest-value fact in the 10-Q, and a reason the gate matters.

Where this leaves us¶

Today: both of us hold zero.

After the 10-Q: I'll concede a starter of at most a third near $241–247 if all of the following hold: - Organic growth is at least ~11%. - The tax note and SBC explain the conversion slip without anything ugly. - Current liabilities and investing outflows are benign.

After the print: I'd add if Q4 gross margin is down no more than ~30 bp YoY and the FY27 guide pairs margin with revenue.

Disagreement that remains: you read +5% with 16% volatility as a reason to start small. I read it as below the cost of equity for a 1.4-beta stock, resting on a thesis (margins stop widening) that Q3 only began to test, and on a multiple that was 16.8x and 12.9x within five weeks. I think the odds are thinner than your table says. If the filing is clean and the print turns gross margin, I'll move toward you. Bear Analyst: # Bear Close: The Earnings Aren't the Risk. The Multiple Is.

Your close is honest: zero today, a starter only after a clean filing, nothing at $254. I'll concede what you've earned, make two points your table can't answer, and then size what we still disagree about.

What I'm conceding¶

Your decomposition and table check out. 1.125 × 0.967 × 0.947 ≈ 1.03, and each row's price follows from its inputs. At a constant multiple every earnings path is positive, so I'll stop arguing that earnings alone sink this.
A Q3 repeat is "mixed," not "exit." It lands on your lines, not past them. The ±15 bp tolerance is sensible.
Your Semrush gate is stricter than mine. I accept it.
The RSU withdrawal is appreciated. It also leaves the below-the-line conversion slip with no benign explanation on the table.

1. If earnings can't hurt you, the table can't test the bear case¶

Your table holds the multiple at 14.2x, and the multiple is where all the risk now sits. Re-run your own "hold" row with a worse margin path:

Op-margin path (revenue +12%, conversion −5.3%, shares −7%)	NI growth	EPS growth	Price at 14.2x
9-month pace (−3.3% relative)	~+3%	~+10%	~$280
Q3 pace (−4.1%)	~+2%	~+9%	~$278
Q2 pace (−5.8%)	~0%	~+7%	~$273

Worsening margins barely move a 12-month EPS table, because about 7 of the roughly 10 points of EPS growth is share count. A framework that stays positive when the bear thesis gets worse can't falsify that thesis.

The multiple is what the market pays for durable margins, and the durability evidence has all pointed one way: - COGS growth went +6.8% → +12.1% → +18.8%. - Gross margin went +50 → +10 → −60 bp YoY. - Net income conversion has slipped for three quarters. - The only line that improved is opex, which is discretionary.

At persistence, breakeven is 12.9x, and ADBE closed at 12.9x on 9/28, three weeks ago. Two of the five dated multiples in our table (11.1x and 12.9x) sit at or below breakeven. Those dates were picked as extremes and aren't a random sample, so read this as illustrative. It still shows that "the low end of the range" is a recent address, not a tail.

2. Semrush answers the revenue question but not the COGS question¶

These inputs are from memory and not in our data: roughly $110M of quarterly revenue and about an 80% gross margin. If fully consolidated in Q3:

	Reported	Ex-Semrush (illustrative)
Revenue growth	+12.9%	~+11.1%
COGS growth	+18.8%	~+15.3%
Gross margin YoY	−60 bp	~−45 bp

Acquisition mix explains about a quarter of the gross-margin decline and 3–3.5 points of COGS growth. COGS would still be growing about 4 points faster than organic revenue. That residual has to be compute, delivery cost or amortization, so "benign mix" doesn't cover it.

Your gate then puts you in a dilemma: - If the deal closed in the quarter, organic growth is about 11%, which your own gate calls a fail. - If it didn't, the whole 18.8% COGS acceleration is organic.

Each state leaves a problem. The subscription cost-of-revenue line and the acquisition note in the 10-Q will tell us which one we're in.

Use your three scenario prices (~$212 retest, $280 hold, $315 at 16x) and vary only the weights:

Entry	Your 30/45/25	My 40/45/15
$254.62	+5.4%	~+1%
$247	+8.6%	~+4%
$241	+11.4%	~+7%
~$235	~+13%	~+10%

At a 10% hurdle, your weights clear at about $244 and mine at about $235. After seven rounds, that is the whole odds disagreement, about 4% of entry price, applied to a third of a position. Neither of us can defend our weights from data we have. Only the print can settle them, and the 10-Q can settle some of it first.

Your line that a clean print lowers the retest weight and raises the price, so "the two roughly offset," is the one claim in your close that wasn't computed. Hold your scenario prices fixed and a +6.8% gap to about $272 takes your own 30/45/25 weights to about −1%. Scenario prices would rise on a clean print too, but you'd need to show that rather than assert it.

What would confirm the bear case¶

Q4 COGS growth above ~20%, or gross margin down more than ~75 bp YoY.
Organic revenue growth below ~11% once acquisitions are stripped out.
An FY27 guide that holds margin by trimming opex and slowing growth.
Financing outflows above FCF with rising debt.
A weekly close below $231.

I'd also accept a clean 10-Q with these items explained: the tax note and SBC, the composition of current liabilities, and the $1.7B of non-capex investing outflow.

Bottom line¶

We agree on process: - Today: no position. At $254.62 under dense resistance, expected return is about +1% to +5% on either set of weights, below any plausible hurdle for a 1.4-beta stock. - After a clean 10-Q: a starter of at most a third at $241–247, which I accept. - After the print: add only on gross margin down ≤ ~30 bp YoY, a guide that pairs margin with organic revenue, and an explanation of the conversion slip.

The two of us differ by about $9 a share on the odds and by a third of a position on timing. The bigger point is that the gating facts (organic growth, cost of subscription, tax note, current liabilities, investing outflows) sit in a filing that has been public for weeks. We spent seven rounds arguing about numbers that a careful read of one document would settle. Until someone reads it, "buy on price discipline" is a plan with its most important input missing.

Research Manager¶

Recommendation: Hold

Rationale: This debate ended closer than its length suggests. Both analysts converged on the same action, and I think they earned that convergence. I'm landing on Hold. The bull's strongest points survived scrutiny. At 14.2x trailing GAAP, the burdened earnings yield is 7.3%; the bull rightly dropped the 9.4% pre-SBC FCF yield. With revenue growing about 13% and diluted shares down about 7% a year, every earnings path in the decomposition table is positive at a constant multiple, roughly +7% to +20% EPS growth. The balance sheet is not a solvency issue: net debt is about 0.25x EBITDA, and financing outflows fell to 91% of FCF from 126%. The bear won most of the specific exchanges, though. The 'accelerating' claim was retired. Nine-month net income grew only 2.9% on 12.5% revenue growth. Conversion of operating income to net income slipped about 4 points in all three quarters, and no benign explanation survived once the RSU tax story was withdrawn. Gross margin went +50, +10, then -60 bp YoY while COGS growth accelerated from 6.8% to 12.1% to 18.8%. Q3's operating-margin improvement came from discretionary opex, not the structural cost line. The bear's sharpest point was that about 7 of the roughly 10 points of EPS growth come from share count, so the earnings table can't falsify the margin-durability thesis. All the risk sits in the multiple. It swung 11.1x, 16.8x, 12.9x, 14.2x in sixteen weeks, and the breakeven multiple if both drags persist (~12.9x) was the 9/28 close. On Semrush, which comes from memory and is not in our data, there are two possibilities. If it closed in the window, organic growth may be about 11%, right on the bull's own kill line. If it didn't, the whole COGS acceleration is organic. At $254.62, both sets of probability weights give roughly +1% to +5% expected return, below any plausible hurdle for a 1.415-beta stock. Tactical reward-to-risk to first resistance (265.60-266.51) against a 2xATR stop is about 0.7:1. Price sits under a dense 255-257 cluster with ADX near 13 and the daily SuperTrend down. Why not Underweight: the bear never argued for exiting. If the margin and conversion drags merely persist, the stock still earns about 10% at a constant multiple, and the downside requires the multiple to compress back to the low end of its recent range. Why not Overweight: expected value at today's price doesn't clear the hurdle, the margin trend hasn't turned, and the gating facts sit in a filed 10-Q that neither side read. Those facts are organic growth, subscription cost of revenue, the tax note and SBC, the composition of current liabilities, and the $1.7B non-capex investing outflow. The remaining disagreement is about $9 a share in entry price ($244 vs $235 to clear a ~10% hurdle) on a third of a position. That is balance, not a directional edge. Data gaps to flag: the FRED calls failed, so there's no 10-year comparison. Rate odds come from thin Polymarket markets. Semrush terms and the ~Dec 9 print date are unconfirmed. There is no RPO or deferred revenue data, and the 10/21 bar is provisional.

Strategic Actions: 1) Current position: no new buying at $254 or above, where expected value is about +1-5% and below hurdle. Holders at or below a standard allocation should maintain. Holders above standard weight should trim back toward standard into strength at $257-267 (first resistance 265.60-266.51), where reward-to-risk is worst. 2) Gate before any new capital: read the Q3 FY26 10-Q, which our tools did not surface. Check (a) the acquisition note: whether Semrush closed, when, and its revenue contribution. Organic growth must be at least ~11% and not decelerating from Q1's 12.0%; treat ~11.1% as a fail. Check (b) subscription cost of revenue and what is driving COGS +18.8%. Check © the tax provision, effective rate, cash taxes paid and SBC expense, to explain the ~4-point conversion slip. Check (d) the composition of the $2.65B rise in current liabilities: deferred revenue vs current debt vs accruals. Check (e) the ~$1.7B non-capex investing outflow, and the mix of financing outflows between buybacks, debt repayment and RSU withholding. If anything is ugly, take no new position, and existing holders should trim to about half a standard allocation. 3) If the 10-Q is clean, buy a starter of at most one-third of a standard allocation. Use limit orders at $241-247 (10 EMA and Bollinger midline), keeping part of that third for $235 or below, where even the bear's weights clear a ~10% hurdle. Do not chase above $247 before the print. Size for a gap, not a stop: a ~7% gap (the 6/12 precedent was -6.8%) on a one-third position costs about 2.3% of intended capital. 4) Q4 print, expected mid-December with the date unconfirmed. CLEAN means gross margin down no more than ~30 bp YoY, organic revenue at least ~11%, an FY27 guide pairing flat-to-up operating margin with ~11%+ organic revenue, and the conversion slip explained. On a clean print, add toward a full standard allocation in tranches. MIXED means gross margin down 30-60 bp (with a 15 bp tolerance), operating-margin compression of 150 bp or less, an ambiguous guide, or no organic breakout. On a mixed print, hold the starter and don't add. BAD means organic growth under 11%, operating-margin compression beyond 150 bp, gross margin worse than -60 bp, COGS growth above 20%, a guide that holds margin by cutting opex while growth slows, or financing outflows above FCF with rising debt. On a bad print, exit the starter, and existing holders cut to Underweight (half a standard allocation or less). 5) Technicals: an alternative add trigger, valid only if the 10-Q gates pass, is a daily close above ~257 with ADX rising toward 20 and OBV above -198.9M. Trim or exit on a weekly close below $231 (the intraday low was 224.67). 6) Re-rate after reading the 10-Q. A clean filing plus a pullback into $241-247 would support Overweight, and a failed gate would support Underweight.

III. Trading Team Plan¶

Trader¶

Action: Hold

Reasoning: The research plan lands on Hold. At 254.62 expected return is only about +1% to +5%, below a plausible hurdle for a beta of about 1.4, and margin and conversion drags have not turned. Technically, price sits under a dense 254.98-257.63 resistance cluster with ADX at 13.14, the daily SuperTrend still down, and reward-to-risk to the 265.60-266.51 resistance against a 2xATR stop of about 0.7:1. The case is not bearish enough to sell, since the stock still earns about 10% at a constant multiple and the weekly SuperTrend is up. The gating facts sit in the Q3 10-Q, which neither the plan nor the technical report covers, so new capital should wait for that read and a pullback.

Entry Price: 244.0

Stop Loss: 231.0

Position Sizing: No new buying at 254 or above. Holders at or below standard weight should maintain, and holders above standard weight should trim toward standard into 257-267 strength. Only after a clean Q3 FY26 10-Q, add a starter of at most one-third of a standard allocation via limit orders at 241-247, keeping part for 235 or below. Size for a roughly 7% gap risk, and exit on a weekly close below 231. Portfolio holdings were not provided, so apply this to your own position.

FINAL TRANSACTION PROPOSAL: HOLD

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: Let me open by pushing back on the idea that Hold is the timid choice here. With ADBE at 254.62, sitting under a stack of resistance from 254.98 to 257.63, Hold is the aggressive position. Aggressive means taking risk where the payoff justifies it, not buying whatever is in front of you. Buying here gives you about 11 points of upside to the 265-266 shelf against about 17 points of risk to a 2xATR stop, roughly 0.7 to 1. Nobody should take that bet on a name with a 1.4 beta. The same trade from a limit fill at 244 with a stop at 231 risks 13 to make 22, about 1.7 to 1. A fill at 241 makes it 2.5 to 1, and a fill near 235 risks about 4 points against a 30-point run back toward the September high. That is the high-reward setup, and the plan is built to get it.

I expect the conservative analyst to say this should be a trim or a sell, so let me take that on first. They will point to the margin slippage, and it's real. Operating margin was 34.8% against 36.3% a year ago, and cost of revenue grew 18.8% in Q3. But operating margin is up from 33.8% in Q2, gross margin is still near 89%, and revenue growth has accelerated from 12.0% to 12.7% to 12.9%. Operating cash flow is the cleaner read, and it grew about 15% in Q3 while the nine-month FCF margin held at 37.8% against 38.3%. A company whose growth is speeding up while it spends on AI is not obviously a broken one.

They will also say EPS growth is just buybacks, with net income up only 1% to 4%. Look at what is being bought. The stock trades at 14.2x trailing GAAP earnings with a roughly 9.4% FCF yield, and the company retires about 7% of its shares a year at that price. That is the best use of capital available to management, and it compounds if the multiple recovers at all. A return to 16x trailing EPS gets you to about 287, nearly the September high, which is hardly a heroic rerating.

On the monthly SuperTrend being down, it's a lagging regime filter that only flips after most of the recovery is done. The weekly trend is up with a stop at 206, and the stock has set a higher low at 231 against June's 193. As for the CEO's $18.3M sale at about $244 in April, it is 94% of the sale value over the year. Everything else is small, and the only priced trade in the last 90 days is a $110K sale. Meanwhile a director put $1.95M in at 194.51 near the lows. That is a mixed record, not a warning. And "business model destroyed" is hard to square with 12.9% growth and a market that has already marked the stock down to 14x.

To the neutral analyst, who I expect to argue for a balanced starter position now to avoid missing the move: ADX is 13, and the technical report itself says breakouts are unreliable in that state. In a trendless range the edge is at the bottom of the range, not the top. ATR is 8.53, so a typical day moves about as much as the pullback we want, and the 10 EMA sits at 247.16, only about 3% below. The daily z-score is 1.95, the TD count is 5, and price is pinned at the upper Bollinger band. We don't have to be right about a drop to be fine waiting. We just need the stock to wander back toward the limit orders, which it does constantly. And the next hard catalyst, probably a December 9 print though that date is unconfirmed, is about seven weeks out. Buying now means carrying a possible 7% gap with a poor entry. Waiting means arriving with a better price and cleaner information.

The trim guidance is also more aggressive than it looks. Holders above standard weight only come back to standard into 257-267 strength, so they keep their winners running while raising cash for the 241-247 orders. That is rebalancing, not capitulation.

On the 10-Q gate, the Q3 statements are already in our fundamentals pull. What's missing is debt maturities, deferred revenue, RPO, SBC and buyback detail. Those answer the real open questions: whether the 0.77 current ratio is just prepaid subscriptions, and whether the 128% FCF-to-net-income ratio holds up after SBC. That is a reading assignment that finishes well before price reaches our orders, so the gate costs nothing. I would use the reserve for 235 or below aggressively, because with a weekly-close stop at 231 the risk there is tiny against a very large reward.

I'll concede the real risks. The 78% December hike pricing comes from a roughly $1M market I wouldn't hang a thesis on, but a hawkish Fed is a genuine headwind for a 1.4-beta software name. Sentiment is thin and partly promotional, and the 10-21 bar is provisional. Those are reasons to size for the gap and honor the 231 exit, not reasons to abandon the position.

So I'd hold, keep the standing limit orders at 241-247 with a reserve below, and get aggressive only when the price pays us for it.

FINAL TRANSACTION PROPOSAL: HOLD Aggressive Analyst: Let me start by giving back what I should, because a few of my lines didn't survive your replies.

The 4-point risk at 235 is gone. The exit is a weekly close. The stock closed at 231.01 on September 28 after trading to 224.67, and a 4-point stop on an 8.5 ATR name is either noise or fiction. You're also right about the monthly SuperTrend. Its stop sits at 401, above the 52-week high of 363.70, so it can't flip in any scenario, including my 287. I called it lagging, but it's uninformative, and it should get zero weight rather than negative weight. Conservative's break-even math holds too. Thirteen over 34.6 is about 38%, and stop geometry alone doesn't create an edge. On the gate, I'll take the sequencing. Read the 10-Q before the orders go live. Pull the 10-year and VIX from somewhere other than the dead FRED feed while we're at it. I'd only ask that we write the pass/fail test down first, so the gate is a test and not a reason to never buy.

Now what survives. The 38% break-even assumes zero drift. A business with a 9.4% FCF yield and a share count falling about 7% a year isn't zero drift unless earnings roll over. Neutral saw that, and it's why the evidence should set size.

On SBC, I'll admit the 9.4% is pre-SBC. But the roughly 7% decline in diluted shares is a net figure, so it already absorbs stock issuance. Do a deliberately generous sensitivity too. If SBC took $2.5B, FCF after SBC is about $6.85B, a 6.9% yield on a $99B cap. That's right at neutral's threshold, and the filing settles it.

On margins, YoY is the right comparison, and gross margin is the real issue. But gross profit still grew about 12% YoY in Q3 on 12.9% revenue growth. The 60 bp gross margin slip is worth about $155M on trailing revenue, under 2% of FCF. The 150 bp operating margin gap is worth roughly 4%. The slope matters, and I want the filing to say whether it's compute or something else. Investing outflows were $1.9B over nine months versus $1.0B last year. If part of that is an acquisition, purchased amortization could explain some of the 18.8% cost growth. That same filing should tell us whether the revenue acceleration is organic, which cuts the other way, so I'm not cherry-picking. Revenue acceleration slowing from 0.7 points to 0.2 is still acceleration, and operating cash flow isn't lagging. It grew 14.8% in Q3. A nine-month FCF margin of 37.8% versus 38.3% is a 50 bp slip on a 38% margin. I'll live with that.

The cash figures are framed at their worst point too. Cash is down 31% from the February peak but only about 12.5% year over year. Financing outflows at 89% of operating cash flow compare with more than 100% last year. The buyback pace slowed.

Conservative's buyback point is the fairest one. Retiring shares at 14x is destructive if the disruption bears are right. But they need revenue to roll over, and revenue growth is accelerating, not slowing. The market already took 30% off the price while earnings kept growing. That's the doubt being paid for, and it's why 13 to 14x is the entry I want.

On the insider point, the CEO sold at about 244 in April, and I won't call that support. But trailing EPS then was about 17.16, back-solving from the quarters rolled off. Today it's 17.91. The same 244 buys a 13.6x business now versus 14.2x then. Same price, more earnings.

On gap risk, the June sequence is real, and the first gap wasn't the last leg. That's an argument for sizing, not for a smaller number picked by feel. Neutral's math is the cleanest in the thread. A third of standard weight at 244 carried all the way to 206 costs about 5% of a standard position. A sixth costs 2.6%. The whole sixth-versus-third debate is about 2.6 points of a standard position in a tail scenario. If the filing passes, I'd take the third.

On the reserve, I concede 231 to 235. Buying within a few points of the exit pays for a stop-out. Neutral's structure is better: main orders at 247 and 243 to 244, a small piece at 238 to 240, and a reserve at 236 to 238 that arms only if the filing passes. The whole block gets one exit, sized for slippage toward the September low. Even on that worst reading, a 235 fill has about 10 points of risk to 224.67 against about 30 to the 265 shelf, roughly 3 to 1. And conservative is right that fills down there come in a selloff, where ADX was near 32. That's what getting paid for liquidity looks like. At 235 you're buying 13.1x earnings and about a 10.2% FCF yield. The thesis there is valuation and cash flow, not trend-following. I don't want "wait for a reclaim" either, because in an ADX-13 market the reclaim signal is the same low-quality evidence we use to dismiss a breakout.

On trimming, I'd side with neutral's ladder. Today's high of 257.63 would already have filled a first rung at 256 to 258, so holders above standard weight get most of what conservative wants without selling into a provisional bar. The TD count also helps. A completed daily 9 needs the October 26 close above 256.73, which means price rises through the first rung. A rejection leaves holders with the position they chose, still at or above standard weight, which is fine.

Neutral's confirmation add is the best idea on the table. A sixth on a retest of 253 to 255 after a daily close above 257, ADX heading toward 20, OBV above -198.9 million and a clean filing keeps the plan from being a one-way bet on a deep pullback. That is aggressive in the right way. We pay up when the market proves something, not when it flatters us. Conservative's "no trend to miss at ADX 13" is also my point. With no trend, missing the move costs us nothing.

So the plan is to hold and read the filing today against a pre-written test. Put orders at 247 and 244, with a small piece at 238 to 240. Arm 236 to 238 only on a pass, with one exit for the block. Ladder sells above standard weight. Add a sixth only on a confirmed retest. Hold is the aggressive position here because we keep our capital until the price or the evidence pays for the risk.

FINAL TRANSACTION PROPOSAL: HOLD Aggressive Analyst: Let me start with what I'm giving up, because Conservative and Neutral are right on four points.

First, the confirmation add. I called it the best idea on the table, but it fails the test I opened with. A fill at 254 is about 12 points to the 266 shelf against 17 to a two-ATR stop, the same 0.7-to-1 bet I rejected at the start. It also depends on ADX and OBV in a market where I've said that evidence is weak. It's dead. If the stock runs to 290 on a takeover story without us, I'd rather miss a run I can't underwrite than pay up for it.

Second, the trim. Neutral is right that "a rejection leaves holders with the position they chose" contradicts a plan that says trim toward standard. I'll take half the excess at 255 and up, the rest on the 262 to 267 ladder, and the remainder on a daily close below the 10 EMA at 247. That is a trend-based trigger I wouldn't use to add, but the asymmetry is deliberate. A false trim costs a slice of excess, and a false add costs capital.

Third, the cap. I never proposed going past standard weight. The plan already says maintain or trim at and above standard, so Neutral is just saying it out loud. The 133% scenario was never on the table.

Fourth, the gate has to be able to fail. A 7% SBC-adjusted yield line is one nearly anything passes. I'll take Neutral's numbers: RPO growth under about 9% against 12.9% revenue growth, or organic growth more than a point below reported, means no new money until December. I'll put my thesis on that RPO number. Conservative is right that revenue lags in a subscription model, which is why RPO and deferred revenue are the leading indicators.

Now the pushback. Neutral's leakage point is the best new idea in this thread, with 77.6% of operating income reaching net income against 81.5%. But the balance sheet already says something about it. Total liabilities are up only $1.2B in a year while current liabilities rose $2.65B, so non-current liabilities fell about $1.4B. That doesn't look like a buyback funded by new borrowing. The cash drawdown over nine months, about $1.1B, also looks like the funding source. So my read is that the borrowing test passes and the debt-maturity question is about timing, not stress. The leakage is more likely tax or lower interest income, and the footnotes will say. I haven't proven that. But two of Conservative's five tests already lean toward a pass before we open the filing, which is what a real gate looks like.

On "a clean filing isn't an edge because the market has seen it," look at the closes: 266.51 on September 4 and 265.60 on September 14, with the heavy-volume days in between. If those were the print, it left no net mark on the price, and the slide to 231 came in the two weeks after. So the low probably wasn't the market reacting to the reported numbers. Either it reacted to something on the call, which is why Neutral's addition of the release and call matters, or it was sector and AI-fear tape. In that case the rebound is the same tape in reverse. We should know which before we buy the second sixth.

That leads to the fight I still want. If a pass can only ever buy a sixth, the gate is a veto with no upside. A sixth bought at 244 and carried to 287 adds about 3% to a standard position. We'd be building a reading list, a checklist and an exit rule to move the account by a rounding error in either direction. Neutral's structure fixes that: evidence earns the first sixth and price earns the second.

I'll take alerts at 241 and 238 instead of resting orders. Distance from the exit is a fair concern. But the checklist needs a written default, or it turns into a debate at the worst moment. Check the 10-year and VIX, then ask whether the drop is about Adobe or about the sector. If it's sector-wide with a clean filing, buy the sixth. If it's Adobe-specific, such as a guidance leak, an executive exit or a lost AI position, don't. Sector moves don't change Adobe's cash flows and company moves do. Conservative says the bounce is sector beta with no Adobe news. I agree, and that's why this rule works.

Conservative's point that liquidity providers get paid only when the seller is uninformed describes a market maker. We aren't earning a spread. At 238 we're buying 13.3x earnings and about a 10% FCF yield with a shared exit, and the checklist screens for the informed seller. Also, FRED is down. Whoever owns the checklist needs a working source for the 10-year and VIX today, or it's a wish.

On valuation, 13x isn't a floor. The market paid 10.6x in June and the CEO sold at 14.2x. I don't need a floor, I need to size for its absence, which is why I'm using 207 as the base case and 190 as the stress. At the 52-week high the stock was about 20 times today's trailing EPS. It's 14.2 now with higher EPS, revenue growth went from 10.7% to 12.9%, and RPO will tell us whether that growth is durable.

So Hold. Do the reading today against written numbers, including the release and call. On a fail, no new money, and holders above standard trim as above. On a pass, rest the first sixth at 247 and 243 to 244, with alerts at 241 and 238 for a live-checked second sixth. Cap the total at standard weight, with one exit on a weekly close below 231, treated as gap-exposed. Buy nothing above 254, and make no other adds before December guidance.

FINAL TRANSACTION PROPOSAL: HOLD Aggressive Analyst: Let me start with what you've earned, since you're right on most of the specifics.

Conservative, the balance sheet read. Neutral's arithmetic settles it for me. A debt-to-equity of 0.58 on $11.76B of equity implies about $6.8B of debt, and total non-current liabilities are only $6.33B, a bucket that also holds long-term deferred revenue, tax and leases. So some of that debt is probably already in current liabilities. I withdraw "two of five tests lean pass." It's a number to read. I'd only add the scale: even if notes are coming due, that's a refinancing or paydown against $9.35B of free cash flow and $4.4B of cash. It belongs on the checklist, not the worry list.

You're also right that lower interest income can't explain the leakage. $0.6B less cash is single-digit millions a quarter, not $90M.

I accept the thresholds. An RPO growth rate near 11% against 12.9% revenue growth is a pass, under 9% is a hard fail, and the zone between is no new money. An unexplained 18.8% jump in cost of revenue is also no new money. In a name whose bear case is margins, an open question should block the buy. The 10-year and VIX source and a confirmed earnings date come first. The FRED outage is a tool problem, and fixing both takes minutes.

The 247 buy is gone. My own opening math says why. From 247 to the 231 exit is 16 points of risk for about 19 to the 265 shelf, roughly 1.2 to 1. At 243.5 it's about 12.5 for 22. The first sixth goes at 243 to 244 and nothing higher. I also accept cancelling resting orders about a week before the print once the date is confirmed.

Now where I won't move. On leakage, you said three straight quarters doesn't look like a one-off. I agree, but that makes it a step, not a drain. The gap between net income and operating income conversion was about 5.6 points in Q1, 3.7 in Q2 and 3.9 in Q3. It isn't widening. A tax-rate step that began around the start of fiscal 2026 laps in Q1 FY27, and net income growth then converges toward operating income growth. Interest on borrowed buyback money wouldn't lap. That's why the effective tax rate by quarter, and whether the gap carries into FY27, goes on the reading list. I'm not claiming it's benign, only that the data doesn't show it growing.

Next, the second-sixth default. Requiring a market-wide drop with the index down, VIX up and no AI headline attached describes a tape that almost never appears in a year when software has traded on AI fear. We've spent three rounds unable to say whether September's 21% slide was the call, the tape or AI fear, and we have weeks of hindsight. A rule that demands clean real-time classification and defaults to no will say no every time. So I side with Neutral. The test is whether anything changed in cash flows or estimates, not whether the letters AI show up in a headline. A named AI substitution story, a competitor release, a customer loss, a guidance leak or estimate cuts is a no. Conservative gets a real veto, with the burden on identifying a specific Adobe negative. If the cause is still unclear after the next session, the answer is also no. And I'll take Neutral's rule of not acting on the alert bar itself. Run the checklist and buy the next session if it still reads clean. That is the human decision in front of the fill that answers the short-put worry, and I'll pay for the bounces it costs.

On "stakes this small argue for a simpler process," Neutral's reframe is the best idea in the last round. A sixth moves the account by about 3% either way, but a standard holding carries seven or eight times that. Dropping to 207 is about 19% of the whole position and 190 is about 25%. The filing read mostly informs the core, not the starter. And nobody had written down what happens to the core. I accept the answer. The new block exits on a weekly close below 231, treated as gap-exposed. The core isn't auto-sold, since at 231 it's about 13x trailing earnings with a free cash flow yield over 10%. But that close forces a written re-underwrite within the week. If the gate failed or the cause is Adobe-specific, the default is a one-third trim. If the gate passed and the cause is macro or sector, the default is hold. A severe fail, meaning RPO under 9% with cost of revenue unexplained, reopens whether standard weight is right at all. I'd add the mirror image. A clean pass gets written down as the reason to hold the core through ordinary noise, so we don't re-argue it mid-drawdown.

The case for Hold as the aggressive choice is this. We won't pay for risk at 254, under a stack of resistance with ADX at 13, an unread filing, and a December hike market we can't verify. But every branch has to do something. A pass buys the first sixth on a 4% dip, and price plus a clean checklist can earn the second at 241 or 238, never within a few points of the exit. Guidance in December is where the real size decision happens. A plan where the gate can fail but a pass never acts isn't caution, it's abstention. If ADBE runs to 290 on a takeover story without us, I'm at peace with that. I can't underwrite that run, and I can underwrite 13x earnings with a 10% free cash flow yield at 238.

So here is the plan. Set the numeric pass/fail tests first. Confirm the rate and VIX sources and the earnings date. Read the 10-Q, the release and the call today. On a fail, no new money, and holders above standard weight trim as agreed. On a pass, rest the first sixth at 243 to 244 and set alerts at 241 and 238 for a next-session, checklist-cleared second sixth. Total exposure is capped at standard weight. Size the new block for a slip to 207 and stress it at 190. Buy nothing above 254, and make no other adds before December guidance. Holders above standard weight trim half the excess at 255 and up, ladder the rest at 262 to 267, and finish the trim on a daily close below the 10 EMA.

FINAL TRANSACTION PROPOSAL: HOLD Aggressive Analyst: Let me start with what I'm taking, because most of the last round improved the plan.

The pre-print rule is the best addition. Any excess above standard weight goes to standard at market a week before a confirmed date, with December 1 as the placeholder. It's the one trim that doesn't need price to cooperate, and it's risk control on size we chose to hold, not capitulation. I also accept counting the block as a full third from the first fill. I was calling a 241 alert "price earning the second sixth" when 241 is 0.35 ATR below the first fill, which is one ordinary day. Keep 238 with Neutral's 235 floor and two clean sessions. It will rarely fill, and I'm fine with that.

I'm taking Neutral's version of the peer test over a flat "point or two," since a band that tight trips on noise. I'd apply the same method to rates and VIX. Define the thresholds as percentiles of the trailing year, written down before looking. That answers Conservative's calibration problem without anyone needing a view while FRED is down. On the core, I'll take the one-third trim when the cause is unclear, with Neutral's way back at classification or December guidance. From 231, a third of the core is about 3.5% of the position avoided if the stock reaches 207, and about 6% at 190. A rebound to 254 forgoes about 3.3%. The payoffs are roughly symmetric, and the tail is protected.

On valuation, you're right and I'll fix my line. The 10% yield at 238 was pre-SBC. The honest cross-check is that 238 is 13.3x GAAP earnings, which are already after stock comp, an earnings yield around 7.5%. Conservative's generous SBC case puts the FCF yield at 7.4%. Two different measures land in the same place, so 7.5% is the number I'll use. I also won't argue the 16x rerating anymore. If net income converges to operating income growth of 6% to 8%, add the roughly 7% share shrink and EPS growth is 13% to 15% at 14.2x trailing. That's a PEG near 1, which is reasonable but not the 0.59 on the screen.

Conservative is also right that I overstated "every branch has to do something." What I meant is that every branch needs a written action, and "no new money" is a written action. What I won't accept is a pass branch that can't buy anything.

Now, three places where I still think the plan leans too far toward comfort.

First, June cuts both ways. Conservative cites 218.80, then 204.02, then 190.12 intraday to show that a weekly-close exit protects nothing. True. But look at what the rule would have done. If the prior weekly close was above 231, which I haven't checked, it fires on Friday June 12 at about 204. The most it could have saved was the last 7% down to 190. The stock then closed at 193 on June 25 and at 292.79 on August 31, a rise of roughly 43% from where the exit would have sold. That is hindsight, and it won't repeat on schedule. But it's why the exit belongs on the new block only, why the core gets a re-underwrite instead of an auto-sale, and why the way back matters. The real gap protection is sizing and the pre-print rules, not the stop.

Second, the plan has a ratchet. Before the print we cancel buys, trim the excess and carry only standard weight. Nothing says what re-risks us afterward. If the second sixth only fills on a drop to 238 with a clean checklist, it mostly won't fill. So write the upside branch now. In December, guidance decides, not price. If RPO is near 11% or better, the margin guide is stable and cost of revenue has an explanation, then the second sixth and any trimmed third come back up to standard, even if the stock is above 254. That's evidence paying, not price chasing, and it's the one place I'd pay up. It's also why a 4% better entry is worth waiting for. The research plan underwrites roughly 10% at a constant multiple, and buying near 243.5 instead of 254.62 adds four to five points to that.

Third, the gate list has to close. We now have the 10-Q, release and call, rate and VIX sources with percentile rules, a confirmed date, and a price pull for the peer distribution. That's an afternoon of work. Time-box it, and don't add gates mid-drawdown, which is how a disciplined plan turns into an excuse. I'd also make "open" checkable. If the filing is silent on a named number, like RPO or the effective tax rate, that's open and means no. If it merely feels murky, it isn't a veto.

The plan, then. Write the numeric tests first: RPO near 11% to pass, under 9% to fail, anything between means no new money. The cost-of-revenue explanation, effective tax rate and whether it persists, debt maturities and borrowing, and organic growth within a point of reported also get tested. Confirm the data sources and the date, then read the 10-Q, release and call. A fail or a named open item means no new money. A pass rests the first sixth at 243 to 244, cancelled by December 1 or a week before the confirmed date. The 238 alert runs with the 235 floor, next-session execution, the relative-move and percentile tests, two clean sessions and no named Adobe negative. Total exposure is capped at standard, with one gap-exposed exit on a weekly close below 231, sized for 207 and stressed at 190. The core holds through the print, with a written re-underwrite on that close and a third off if the cause is unclear. Holders above standard take half the excess at 255 and up, the rest at 262 to 267, finish on a daily close below the 10 EMA, and sell whatever remains at market a week before the print. Buy nothing above 254, and make no technical adds.

That is Hold as the aggressive choice: patient where price doesn't pay us, and willing to pay up when December proves something.

FINAL TRANSACTION PROPOSAL: HOLD

Conservative Analyst¶

Conservative Analyst: I'll start with where the aggressive analyst and I agree, because it narrows the argument. Neither of us wants to buy at 254.62. We get there for different reasons, though, and the differences are where the risk is.

The reward-to-risk framing is doing a lot of work in that argument, and it doesn't carry the weight. A ratio of 1.7 to 1 or 2.5 to 1 tells you what you make when you win versus what you lose when you lose. It says nothing about how often you win. Take the 244 entry with a stop at 231 and a target at 265.6. In a range with no drift, which is what an ADX of 13 describes, the chance of reaching 265.6 before 231 is about 38%. At 1.7 to 1 that is exactly break-even. The 254.62 entry they reject works out the same way: a 61% chance of the small win offsets the 0.7 to 1 payoff. A lower entry price isn't an edge, only evidence is. This also means I'd lean less on the trader's 0.7 to 1 line and more on the real reason to wait, which is that the information that would give us an edge isn't in hand yet.

The "risk of about 4 points" at 235 is an artifact of where the line is drawn. The exit is a weekly close below 231, so it doesn't cap the loss at 4 points. On September 28 the stock closed at 231.01 but traded to 224.67 intraday, six points through that level in one session. ATR is 8.53, so a 4-point stop is less than half a normal day's move. Either it's an intraday stop that noise takes out, or it's a weekly-close stop that lets you lose 10 to 15 points. The tiny risk isn't real. Also, the stock only gets to 235 by losing the 10 EMA, the 241 Bollinger midline and the 200 SMA. The last time it sat at 231, ADX was near 32, RSI was 34.5 and the MACD histogram was deeply negative. That was a trend, not a range, so the "edge is at the bottom of a trendless range" logic doesn't apply where the reserve orders sit.

On the 10-Q gate, the aggressive analyst says the reading finishes well before price reaches the orders. The top order at 247 is basically the 10 EMA, and one ATR below here is 246. That's a day or two of ordinary movement. The Q3 statements are already in our own pull, so the filing exists. Read it first, then place the orders. That costs a day, whereas live orders against an unfinished gate is a bet on timing. Resting limit orders also fill when someone is eager to sell to you, which means a hawkish Fed repricing or a fresh AI-disruption headline. The FRED calls all failed, so we have no VIX, 10-year, CPI or policy-rate reading. The 78% hike line is thin, but 97% no cuts in 2026 sits in a $9M market. We'd be leaving buy orders in a 1.4-beta name without knowing the rate regime.

On margins, "up from 33.8% in Q2" compares against the trough. Year over year, operating margin was down about 210 basis points in Q2 and 150 in Q3. Gross margin has gone 89.6, 89.2, 88.7, three straight declines, while cost of revenue growth went from 6.8% to 12.1% to 18.8%. "Still near 89%" is the level, and the slope is what matters. For a company whose bear case is AI compute costs and AI substituting for its product, gross margin is a leading indicator. Revenue growth lags, because subscription revenue is recognized over contract terms. Even the revenue acceleration is fading: it added 0.7 points and then 0.2. Operating income growth trailed revenue growth in all three quarters, and net income grew 1% to 4%. The nine-month FCF margin slipped from 38.3% to 37.8%, which isn't quite "held."

The valuation case also leans on a 9.4% FCF yield that is before stock-based compensation, and the aggressive analyst admits SBC is missing. If SBC is large, the real yield is lower. And 14x earnings isn't a margin of safety by itself. The stock fell about 30% from its high while EPS kept growing, which means the market isn't mismeasuring earnings. It's pricing doubt about how durable they are.

The buyback argument is conditional on the very thing being debated. Financing outflows are about 89% of operating cash flow, cash is down 31% since February, the current ratio is 0.77, and working capital swung by nearly $3B in a year. Retiring 7% of the shares at 14x is smart if earnings power holds and destructive if the disruption bears are right. With net income up about 3% and the share count down 7%, the buyback is doing nearly all the work in EPS.

On the monthly SuperTrend, calling it a lagging filter misses the arithmetic. Its stop is 401.26, above the 52-week high of 363.70. It won't flip in any scenario the aggressive analyst lays out, including their 287 target. By that tool, every rally here is counter-trend. Using the weekly uptrend as comfort doesn't help either. The weekly stop is 206, about 19% below price, and nobody will use that as a risk limit, though the June low of 190 shows the stock has been that low in the last five months.

On insiders, the CEO sold 75,000 shares at roughly 243 to 245, which is where the aggressive analyst wants to place a limit order. The stock then fell about 20% in two months. The director's purchase was one-tenth the size, and no officer bought on the open market at any price all year. I wouldn't call that a warning, but I wouldn't call it support either. The CFO change around the same time is a flag to verify.

On the 7% gap assumption, the June sequence went from 218.80 to 204.02 and then to an intraday 190.12 within a week. The first gap wasn't the last leg. Earnings are about seven weeks out, and a weekly-close stop does nothing through a gap.

I'd also push back on trimming only into strength. Today's high of 257.63 already touched the bottom of that zone, and the stock closed three points under it, pinned below five resistance levels within 2.7 points, with a daily z-score of 1.95 and a TD count of 5. If it rejects here, holders never get the 262 to 267 fills.

The neutral analyst hasn't spoken, but if the case is a starter now so we don't miss the move, the stock is already up about 10% in three weeks, and with ADX at 13 there's no trend to miss.

I'm not arguing for a sale, since the company's cash generation is real. But I'd tighten the plan in five ways: - Clear the 10-Q gate before any orders go live. - Cut the starter to about a sixth of standard weight until we see December guidance, sized as if the stop won't fill and the stock tests 206. - Don't deploy the reserve below 241 on a resting limit, and wait for a reclaim. - For holders above standard weight, trim part of the excess now and the rest into strength. - Treat the weekly-close exit as a gap-exposed level, not a protected one.

FINAL TRANSACTION PROPOSAL: HOLD Conservative Analyst: You've both moved toward me, so I'll start with what I'm taking from you. Neutral is right that my break-even math applies to a sixth as much as a third. Aggressive is right that year-over-year is the fairer cash comparison. And Neutral's trim ladder is close to what I asked for. But the plan you've converged on is looser than it sounds, and the loose spots all lean the same way.

Start with the 10-Q gate. You've agreed to read it before orders go live, which I'm glad of, but look at the test. Neutral's pass line is an SBC-adjusted FCF yield around 7%. Aggressive's deliberately generous case, $2.5B of SBC, comes out at 6.9%. The data we already hold points the same way. Financing outflows run about 9% of market cap a year while the net share count falls about 7%, which implies roughly $2B a year of issuance and an adjusted yield near 7.3%. That's rough, since financing includes debt flows, but the test is built so almost any plausible number passes. A gate that can't fail isn't a gate. The tests that could fail are these:

Whether RPO and deferred revenue are growing at least as fast as revenue.
Whether the 12.9% growth is organic, given that investing outflows nearly doubled.
Whether the cost-of-revenue jump is compute or purchased amortization.
Whether the jump in current liabilities includes debt maturities.
Whether the buyback is being funded with borrowing.

Write those down with numbers before anyone opens the filing, as Aggressive asked. And attach the gate to every order. As Aggressive wrote it, only the 236-238 reserve is conditional, while 247 and 244, the orders most likely to fill, go live regardless.

Also, a clean 10-Q isn't an edge. The Q3 numbers are weeks old, and the heavy-volume days on September 10 and 11 line up with when they'd have come out, though I can't confirm that. The stock went from 292.79 on August 31 to 231.01 on September 28, down 21% in four weeks, and has since bounced to 254. A clean filing means no bad surprise. It doesn't mean the market is mispricing anything. So a clean read earns the starter, not more. The real unknowns, margin trajectory and guidance, get answered in December. Neutral's closing line, a small position that leaves room to add after guidance, is my sixth. The only dispute is whether a clean 10-Q earns the second piece early, and I say no.

Next, consistency. Neutral rejected "wait for a reclaim" because it relies on trend signals in an ADX-13 market. Aggressive agreed, then called Neutral's confirmation add the best idea on the table. That add needs a daily close above 257, ADX heading toward 20 and OBV above -198.9M, all trend signals in an ADX-13 market. You can't discard one and keep the other. The geometry doesn't improve either. A retest fill at 254 still has about 12 points to the 266 shelf against about 17 to a 2xATR stop, the same 0.7-to-1 bet Aggressive rejected at the start. It also lands near a daily TD sell setup that could complete as early as October 27. I'd drop that add until after the print.

I'll give up "wait for a reclaim" in exchange for something simpler: no resting buy order below 241. A ladder of resting buys has the payoff of a short put. It fills in a break and does nothing in a rally. Aggressive calls that getting paid for liquidity, but liquidity providers only get paid when the seller is uninformed, and we can't know that in advance. Neutral says a hawkish Fed hurts holders too. True, but that's why we don't add exposure into it, and resting orders add the most exactly when the macro goes wrong. If the stock reaches 241, we'll know why, we'll have the 10-year and VIX, and we make a live decision.

On valuation, 13x is not a floor. The CEO sold at about 244 in April, 14.2x trailing EPS. Two months later a director bought at 194.51, about 11x. The June low of 190 is about 10.6x today's EPS. The market has shown it will pay that. The 16x rerating to 287 is also where the stock was on August 31, and it gave back 21% within a month.

On drift, the 9.4% FCF yield accrues over years. Over seven weeks it's about 1.3%, against a stock whose ATR is 3.35% of price a day. That's rounding error.

On sizing, Neutral's tail runs to 206. The June intraday low was 190, so the real tail from 244 is about 22%, costing about 7.4% of a standard position for a third and 3.7% for a sixth. Neutral also said to size for a slip to 224 in one paragraph and to survive a 15% gap in another, and 15% off 244 is 207. And for anyone already at standard weight, a third on top means about 133% of standard heading into an unconfirmed December date.

On trimming, Aggressive says today's 257.63 high would already have filled the first rung. That's true only for an order resting yesterday. That rung is also only a third of the excess, and the rest needs 262-267 through five resistance levels and a TD count heading toward exhaustion. Holders above standard weight carry the most exposure into the print. I'd take half the excess off now and ladder the rest.

Finally, the bounce itself. Adobe rose 2% on someone else's $5.7B deal, no headline names Adobe as a participant, and Salesforce fell 2% as the acquirer. monday.com, DocuSign, Intuit and MongoDB moved with it. That's sector beta on no Adobe-specific news, and it can reverse just as non-specifically.

My plan is to write numeric pass/fail tests, read the 10-Q, and pull the 10-year and VIX first. Every order is conditional on the result. The starter is a sixth, with orders at 247 and 243-244 and nothing resting below 241. Size for a failed exit toward 190-207, not 224. No confirmation add before December guidance. Trim half the excess now and ladder the rest.

FINAL TRANSACTION PROPOSAL: HOLD Conservative Analyst: I'll start with what you've earned. Alerts at 241 and 238 instead of resting orders fix most of my short-put objection, because they put a human decision in front of the fill. The cap at standard weight answers my 133% problem. Sizing off 207 with 190 as the stress case is right. Half the excess off now, a ladder for the rest and a 10 EMA backstop is the trim I asked for, so I'll stop arguing those. What's left is where the plan still lets hope stand in for evidence.

Aggressive's balance sheet read is the most confident claim in the thread, and I think it runs backwards. Current liabilities are up about $2.65B in a year and total liabilities only $1.2B, so non-current liabilities fell about $1.4B. You read that as no new borrowing. It's also the signature of long-term notes sliding into the current bucket as they near maturity, which is what the fundamentals report told us to check. If that's what happened, the maturity question is about a refinancing. Cash is $4.4B, net financing outflows run about $2.3B a quarter, and a rates market that is thin but pricing a hike sits in the background. I'm not calling it stress. The same numbers fit two stories, which is why we read the filing instead of announcing that two of five tests already lean pass.

The leakage guess has the same problem. Lower interest income can't be it. Cash is down only about $0.6B year over year, which is single-digit millions a quarter of interest, nowhere near $90M. That leaves tax or something else, and a gap that has run four to six points for three straight quarters doesn't look like a one-off.

The thresholds also got looser as they were written down. Neutral's RPO fail line is 9% against 12.9% revenue growth. An RPO figure of 9.5% would pass, yet it points to growth falling three or four points, which erases the acceleration the bull case stands on. A gate that passes a deceleration isn't a gate. I'd put the line within about two points of revenue growth, so near 11%. And "unexplained cost of revenue allows the first sixth" has the burden backwards. The filing is supposed to explain an 18.8% jump. If it doesn't, we have an open question about margins in a name whose bear case is margins, and open should mean no new money. I'd also add two preconditions: a working source for the 10-year and VIX, and a confirmed earnings date. Right now the checklist can't run, and we don't know how far away the print is.

There's a contradiction in the trim too. Completing the trim on a daily close below 247 says that losing the 10 EMA is bad enough to sell the excess. Yet the first buy order sits at 247. The same level can't be a sell signal for one account and a buy for another. I had 247 in my own plan, and I'm withdrawing it. The first sixth starts at 243 to 244 and nothing above.

The checklist's central question, whether a drop is Adobe or the sector, is a false split for this stock. The bear case is that AI disruption hits application software as a group and Adobe's creative tools in particular. A software-wide AI scare is that thesis showing up in price. Aggressive says sector moves don't change cash flows, but the market is pricing exactly the claim that they will. So the default should be no. A yes should require a market-wide drop, with the index down, VIX up, software moving with beta and no AI headline attached. Otherwise we're buying into the main transmission mechanism of the risk.

September points the same way. The stock fell from 292.79 on August 31 to 266.51 on September 4, before the heavy-volume days we think were the print. It was flat through those days, then fell to 231 by September 28, down 21% in a month. Aggressive's best explanation for the slide is the call or AI-fear tape. Then it bounced 10% on what we all agree is sector beta. When the price swings 10% in both directions on causes nobody here can name, I get more worried about the unknown, not less.

Aggressive says a gate that only buys a sixth has no upside, since a sixth carried to 287 adds about 3% to a standard position. True. But the same sixth carried to 190 costs about 3.7%. That's a small bet with roughly symmetric tails, at an entry a filing the market already read can't improve. Stakes that small argue for a simpler process, not a bigger position.

On earnings, a weekly-close exit does nothing through a gap. March and June both gapped on heavy volume, and June ran from 218.80 to an intraday 190 within a week. Once the date is confirmed, resting orders should be cancelled about a week before the print.

So my plan is: - Write the tightened gate down first. - Confirm the rate and VIX sources and the earnings date. - On a pass, rest the first sixth at 243 to 244 only. - Keep the alerts at 241 and 238 with a default of no, and allow the second sixth only on a market-wide drop with no AI headline. - Cap the total at standard weight, with one exit on a weekly close below 231 treated as gap-exposed. - Size for 207 and stress-test at 190. - Cancel resting orders before the print. - Trim half the excess now, ladder the rest, and finish the trim on a close below 247.

FINAL TRANSACTION PROPOSAL: HOLD Conservative Analyst: Where I'm giving ground first, because the gap is much smaller than it was. The gate now has numbers that can fail: 11% RPO growth to pass and under 9% as a hard fail. The 247 buy is gone, total exposure is capped at standard weight, and alerts replace resting orders at the lower levels. The next-session rule puts a human decision in front of the fill. The trim ladder with the 10 EMA backstop is what I asked for. Neutral's point about the core was the best addition of the last round. And Aggressive is right that the net-income-to-operating-income conversion gap hasn't widened: by my math it was 5.6, 3.7 and 3.9 points. What's left is four places where the plan still leans on something it hasn't earned.

First, the core. The re-underwrite on a weekly close below 231 defaults to hold if the gate passed and the cause is macro or sector. That branch needs a live classification of the drop, and Aggressive just told us that three rounds and weeks of hindsight haven't let us classify September. For buying, you made "unclear" mean no. For the core, unclear should mean the one-third trim, for the same reason.

I'm also uneasy about writing down that a clean pass is the reason to hold through ordinary noise. The pass reads a quarter that ended August 28, and it goes stale at the December print. A close below a level the stock already held once is new information, and a precommitment shouldn't override it. The bigger problem is that a weekly-close exit does nothing in a gap. June went from 218.80 to an intraday 190.12 in about a week, so a re-underwrite "within the week" happens at 205.

The core carries seven or eight times the risk of the starter. So I'd add one rule that costs nothing: any excess above standard weight still on the book a week before a confirmed print gets trimmed to standard at the market. We already cancel the resting buys a week out, and the excess shouldn't be the one piece of the book that goes into the gap at full size.

Second, the ladder isn't really a ladder. The first sixth is at 243 to 244 and the exit is 231, which is 13 points, or about 1.5 ATR. The alerts at 241 and 238 are 0.35 and 0.7 ATR below 244. So "price earns the second sixth" means a normal day's range earns it. In practice the block is a third bought in one move, averaging near 241, with an exit 10 points away and exposed to gaps. There isn't room between 244 and 231 for two independent price-earned decisions. If the second sixth stays, I'd drop the 241 alert and keep only 238. And I'd count the block as a full third from the first fill when sizing for 207 and stressing at 190.

Third, the checklist. The split you've settled on is that generic sector selling is eligible, while a named AI story, a competitor release or estimate cuts are not. That judges narrative in real time. In a year when the sector narrative is AI disruption, the label will tend to be whichever one permits the trade. I'll accept the split, since a pure default-no almost never fires, but then the test has to be numeric, which is what Aggressive demanded of the gate.

Compare ADBE's move over the alert window with the names the news already groups it with: ServiceNow, Intuit, Salesforce, monday.com, DocuSign and MongoDB. If ADBE is more than a point or two worse than their median, it's Adobe-specific and the answer is no. The same goes for rates. The checklist says check the 10-year and VIX but gives no number, and a check without a threshold is no check. Set the numbers before looking. I can't calibrate them while FRED is down, which is another reason fixing the data source is a precondition.

"Nothing changed in estimates" is also a weak test one session after a drop, because cuts and downgrades lag by days. For the second sixth I'd want two clean sessions, with the first sixth already filled.

Fourth, the leakage and the valuation. A tax step is plausible, but lapping it improves the growth rate, not the level. If it began around the start of FY26, Q1 FY27 compares against a lower base and net income growth looks better, while the earnings the 14.2x multiple is paid on don't change. Convergence to operating income growth also puts net income growth around 6% to 8%, since operating income grew 6.1% and 8.3% in Q2 and Q3. That is still below 12.9% revenue growth.

And "13x earnings and a 10% FCF yield at 238" still uses the pre-SBC figure we agreed isn't the test. At 238 the yield is about 10% only if SBC is zero. Aggressive's own generous case of $2.5B puts it near 7.4%.

I'm comfortable with Aggressive's closing line that missing a 290 takeover run is acceptable, because we can't underwrite it. But I'd push back on the idea that every branch has to do something. On a gate that returns open or fail, doing nothing is the right branch. The most valuable action in this plan is the one on the core, and nobody had proposed it until this round.

So my version is this. Write the numbers first, confirm the rate and VIX sources and the earnings date, and read the 10-Q, release and call. A fail or an open question means no new money. A pass earns the first sixth at 243 to 244 and nothing above 254 at all. The second sixth comes only at 238, through the numeric checklist and two clean sessions. Total exposure is capped at standard weight, with one gap-exposed exit for the block. The core gets a re-underwrite on a weekly close below 231, defaulting to a one-third trim when the cause is unclear, and the pass expires at the print. Holders above standard trim half the excess now, ladder the rest at 262 to 267, and finish on a daily close below the 10 EMA. Anything still above standard a week before the print goes at the market, and the resting buys are cancelled then too.

FINAL TRANSACTION PROPOSAL: HOLD Conservative Analyst: Between the three of us the plan is now close to one plan, so what's left is the places where its wording still leaves a door open. I'll start with what I'm taking.

Aggressive, your correction on valuation is the honest one. A 7.5% GAAP earnings yield at 238 and a PEG near 1 describe a fair price for a good business with open questions, not a bargain, and I'll stop arguing valuation is a trap. I also accept that "no new money" is a written action. Neutral, you're right that a trim with no way back is a ratchet.

The way back is still wrong, though. Both of you wrote that the trimmed third returns when the cause of the drop is classified as macro or sector. That is the same real-time narrative judgment Aggressive said we couldn't make about September even with weeks of hindsight. If the exit is a weekly close below 231, the re-entry should be as mechanical as the exit. I'd use December guidance, or earlier only if the stock is back above 231 on a weekly close and the numeric checklist has passed two sessions in a row. The way back should be slower than the way out, because the whole point of the trim is that we don't trust our ability to read the move live.

On Aggressive's December upside branch, I agree with the principle, but it's the place where the plan is most likely to quietly abandon its own discipline. The market prices the evidence in the first session. If RPO, the margin guide and cost of revenue all come in clean, the stock gaps up and we re-risk at a higher price, which is the same poor entry geometry this plan refuses at 254 today. Evidence paying and price paying collapse into one thing, because you pay for the evidence in price. So I'd write the numbers now and wait two sessions after the print. I'd also restore the trimmed core before any second sixth, since the core is size we already underwrote. And the full annual filing normally lags the release by weeks, so the December gate will be the release and call alone.

The gate list also tests the smaller part of the problem. Q3 cost of revenue works out to about $764M against about $641M a year ago, an increase of about $120M. But the operating margin slip is about 150 bp, of which gross margin is only 60. The other 90 comes from opex, which grew 14.8% against 12.9% revenue growth. So roughly 60% of the margin drift sits in R&D, sales and G&A, where nobody has written a test. We also have the net income leakage of roughly $90M a quarter below the operating line. Cost of revenue, opex and leakage together make up the margin story, and the gate should test all three: what drove opex growth, whether it's recurring, and whether the effective tax rate is guided to persist.

I'd also tighten Aggressive's definition of "open." Counting it only when the filing is silent on a named number is too narrow, because a vague line like "higher infrastructure costs" is not an explanation. Make it numeric. The filing has to attribute roughly three quarters of the cost-of-revenue and opex increases to named drivers and say whether they recur. Otherwise it's open, and open means no new money.

The peer test needs one fix. Calibrating the Adobe-specific threshold on the trailing distribution of ADBE's two-day relative move sounds right, but that distribution includes the four heavy-volume gap windows we've been treating as prints. Those are the fattest tails, so they inflate the standard deviation and loosen the band that's supposed to catch Adobe-specific selling. Exclude earnings windows from the calibration. And I'd put a basis-point change for the 10-year next to the percentile rule, since a percentile of a stressed year can't tell you what regime you're in. I also haven't checked the FOMC calendar, but if a meeting falls near December 9, we have two scheduled shocks in the same week, and the reading list should include that date.

On the buyback, the 13% to 15% EPS growth behind a PEG near 1 needs the 7% share shrink to continue. Financing already runs about 89% of operating cash flow while cash is down 31% and the current ratio is 0.77. The same dollars also retire fewer shares as the stock rises, so the accretion shrinks as the bull case works. That makes it a best case, not a base case.

I accept Aggressive's June point that the stop is a coin flip. The stock went from 193 to 293 to 231 to 254 in four months, so sizing and the pre-print rules are the real protection, as you said.

My version is this. Write the numeric tests first, covering RPO, cost of revenue, opex, leakage and organic growth. Confirm the rate and VIX sources and the earnings and FOMC dates. Read the filing, release and call. A fail or an unexplained item means no new money. On a pass, rest a sixth at 243 to 244 and cancel it by December 1 or a week before the confirmed date. Allow the second sixth only at 238, above the 235 floor, through the numeric checklist and two clean sessions. Cap total exposure at standard weight. Treat the weekly-close exit at 231 as gap-exposed, and size for 207 with 190 as the stress case. The core gets a written re-underwrite on that close, with a one-third trim by default, and a mechanical way back. Holders above standard trim half the excess now, ladder the rest at 262 to 267, finish on a close below the 10 EMA, and sell anything still over standard a week before the print.

FINAL TRANSACTION PROPOSAL: HOLD

Neutral Analyst¶

Neutral Analyst: You two are closer than your tone suggests, and each of you leans on an argument that can't carry the weight you put on it.

Aggressive first. The "4 points of risk" at 235 is the weakest number in your case. The exit is a weekly close below 231, and on September 28 the stock closed at 231.01 after trading down to 224.67. With ATR at 8.5, a 235 fill either gets stopped by noise or lets you lose 10 to 15 points. Your deepest reserve orders also sit where ADX was 32 and the MACD histogram was deeply negative. That was a trend, not the bottom of a range. You wave off the monthly SuperTrend as lagging, but its stop is at 401, above the 52-week high, so it can't flip in any scenario you describe. It's uninformative, and so is the weekly stop at 206, since nobody will risk 19%. Your buyback case also rests on a 9.4% FCF yield that is before stock-based compensation, which we haven't seen. Financing outflows are 89% of operating cash flow and cash is down 31% in two quarters. That may be fine, but you don't know yet.

Conservative, your break-even math is right: 13 over 34.6 is about 38%. But it proves too much. In a zero-drift world every entry is zero expected value, including your sixth-size starter. It tells us stop geometry creates no edge, which I accept. It assumes zero drift, though, and a business throwing off a 9.4% FCF yield while retiring 7% of its shares isn't zero drift if earnings hold. Whether they hold is exactly what the 10-Q answers. So the fix is to get the evidence, not to shrink to a sixth no matter what it says. The risk saved is also tiny. A third of standard weight bought at 244 and carried to 206 loses about 16% on a third, roughly 5% of a standard position. A sixth cuts that to 2.6% and gives up most of the upside if you're right.

Your margin evidence also cuts both ways. You cite operating margin down 210 basis points in Q2 and 150 in Q3 as deterioration, but that gap narrowed by 60 points, and opex growth eased from 17.2% to 14.8%. Your real point is gross margin. Year over year it went +50, +10, then -60 basis points, while cost of revenue growth went 6.8%, 12.1%, 18.8%. Last year's Q1 to Q3 was flat, so it isn't seasonal. That's a real slope, and the filing should say whether it's compute costs or acquisition amortization. Finally, "wait for a reclaim" relies on trend signals in an ADX-13 market, the same weakness you use to dismiss a breakout entry. And a hawkish Fed hurts anyone holding the stock, not just someone whose buy order fills 4% lower.

Here is where I land. Hold is right, but it needs to be executable.

First, read the 10-Q today. You both agree the statements are in our pull, so this costs a day, not weeks. Pull SBC and buyback dollars to get FCF after SBC, deferred revenue and RPO to test the 0.77 current ratio, debt maturities, and what's driving cost of revenue. Then let the result set the size instead of arguing it. If SBC-adjusted FCF yield is still around 7% or better and the cost-of-revenue jump has a benign explanation, the full third is allowed. If it looks like structural compute cost and conversion shrinks after SBC, drop to a sixth and keep nothing in reserve until December guidance.

Second, placement. Put the main orders at 247 and 243 to 244, with a small piece at 238 to 240 near the Bollinger midline. Arm the reserve at 236 to 238 only if the filing passes. I wouldn't rest anything at 231 to 235, because buying within a few points of your exit in a name that moves 8.5 a day just pays for a stop-out. Treat the whole block as one position with one exit, and size it assuming the exit slips to the 224 September low.

Third, trimming. Aggressive wants to wait for 262 to 267, and conservative wants to trim now. Today's high of 257.63 touched the zone and closed back below it, but the bar is provisional, so I wouldn't dump. Holders above standard weight can set resting sells: a third of the excess at 256 to 258, another third at 262 to 265, and the rest at 267 or higher. Nobody should go below standard weight, since the cash generation doesn't justify that.

Fourth, earnings. Neither of you asked whether the starter rides through December 9, which is unconfirmed. There were gap-downs in March and June, and the June sequence ran to 190 intraday. I'd hold a starter sized to survive that and save the second half for after guidance.

Fifth, don't chase, but don't be rigid either. The daily TD count could complete a 9 as early as October 27 if closes hold above 256.73 and 254.62, so a breakout this week would arrive into a finished sell setup, with ADX still low and OBV unconfirmed. Keep the no-buy rule above 254 for now. If the stock does confirm, with a daily close above 257, ADX heading toward 20, OBV above -198.9 million and a clean filing, I'd allow a sixth on a retest of 253 to 255. A stock rerating on a software M&A story may never revisit 244, and a plan that works only on a deep pullback has its own cost.

One last point: nobody should cite the 92% bullish StockTwits ratio. Half the bullish tags come from one account, and others are sarcastic or off-ticker.

So it's a small, evidence-sized position that survives a 15% gap and leaves room to add after guidance.

FINAL TRANSACTION PROPOSAL: HOLD Neutral Analyst: Both of you have moved toward the middle, so I'll start with my own errors, since Conservative caught two.

I told you to size for a slip to 224 in one paragraph and for a 15% gap in another. Those aren't the same thing. Fifteen percent off 244 is 207, and the June low was 190. I'll size on 207 as the base case and treat 190 as the stress test. The confirmation add also leaned on ADX, OBV and a daily close in a market where I'd just said those signals are weak. I'm dropping it as written. If the stock proves something before December, I want the proof to be fundamental.

The bigger problem is that you're both arguing about the wrong object. Aggressive keeps using the 9.4% yield and the shrinking share count to rescue a trade with a stop 13 points away. Conservative keeps applying zero-drift break-even math to that same trade. Conservative is right that over seven weeks the yield is worth about 1.3% against a 3.35% daily ATR, so drift can't justify an entry. But the reason to own ADBE at all is a multi-quarter holding period, where drift isn't zero if earnings hold, so break-even math doesn't settle it either. This is an investment-sizing problem with a stop attached as a thesis check. That's why I keep landing on a position small enough that we don't need the answer before December.

On the gate, Conservative is right that my 7% line was one almost anything passes. SBC-adjusted yield is a floor, not a test. The tests that can fail are the ones Conservative listed: RPO and deferred revenue growth against the 12.9% revenue growth, whether that growth is organic given investing outflows nearly doubled, what is driving cost of revenue, and whether debt maturities or borrowing are funding the buyback.

I'd add one nobody has raised. Net income as a share of operating income was 77.6% in Q3 against 81.5% a year ago. The same gap shows in Q1 and Q2, four to six points each quarter. In Q3 that is roughly $90M, or about $370M annualized. That is more than twice the dollar cost of the 60 bp gross margin slip Aggressive sized, and about the same as the entire operating margin drift. It sits below the operating line, and none of us knows whether it's tax, interest or something else. A one-time tax step-up rolls off. Higher interest on borrowed buyback money does not. That tells us more about the 14.2x GAAP multiple than SBC does.

Write the thresholds down before anyone opens the filing. My numbers: RPO growth below roughly 9% against 12.9% revenue growth, or organic growth more than a point below reported, is a fail and means no new money until December. Unexplained cost of revenue or leakage below operating income allows the first sixth only. A clean read allows the first sixth now and makes the second eligible on price. Also add the earnings release and call to the reading list. The 10-Q has no guidance commentary, and if the September 10 and 11 volume was the print, that's where the explanation for the slide to 231 lives.

Conservative says a clean filing is no edge because the market has seen it. I agree, and that's why a pass can't be what buys the second sixth. But if the filing carries no information, the gate is theater. It works mostly as a veto: a fail is a reason to stay out, and a pass is only the absence of one. Evidence earns the first sixth, and price has to earn the second. That puts me between you. Aggressive wants a third on a pass, and Conservative wants a sixth no matter what.

On resting orders, Conservative's short-put point is fair, but it applies equally to 247 and 244, which Conservative keeps. The real difference is distance from the exit. So here is a version I can defend. After the gate passes, rest orders at 247 and 243 to 244 for the first sixth. Set alerts at 241 and 238 rather than orders. When an alert fires, run a written checklist: 10-year, VIX, and whether the headline is Adobe-specific or sector-wide. If it's clean, deploy the second sixth. Write the checklist now, because the live decision in a selloff is where discipline fails. Conservative gets the live decision, and Aggressive gets to buy lower.

Total exposure should also be capped at standard weight. The trader's plan already says holders at or below standard maintain, so the starter is for flat or underweight accounts and fills up to standard, never past it. That answers the 133% problem without shrinking everyone to a sixth. On the tail, a third at 244 costs about 5% of a standard position at 207, and about 7% at 190. I'm comfortable with that if it only happens after both tranches fill, which is the scenario where we were buying a decline on a clean filing.

On trimming, you're fighting over about 1%. ATR is 3.35%, so selling at 254.6 versus 256 is noise. What matters is the amount and what happens if there's no fill. I'd take Conservative's half of the excess, with orders at 255 and above, which is essentially now. Aggressive gets the rest on a ladder at 262 to 267. I'd add a backstop neither of you offered: complete the trim to standard on a daily close below the 10 EMA at 247. That answers Conservative's worry about never getting the higher fills. Aggressive's line that a rejection leaves holders with the position they chose contradicts the plan. If a rejection doesn't force the trim, there is no trim. I also wouldn't lean on the TD count either way. It's a 5 on the daily with weekly and monthly at 1, and one weak close resets it.

I'll push on Conservative's last point as well. A plan that fills a sixth only after a flawless filing and a 3% to 4% dip, with no response of any kind until a December 9 date that isn't confirmed, is the same reaction whether the stock goes to 290 or 230. That's defensible risk control, but it is close to not owning the stock. A gated second sixth on a clean pullback is how this plan can still work if you're wrong about the bear case.

So here is the plan. - Do the reading today against written numbers, including the release and call. - On a fail, no new money, and holders above standard trim as above. - On a pass, rest the first sixth at 247 and 243 to 244, with alerts at 241 and 238 for the live-checked second sixth. - Cap the total at standard weight, with one exit for the block on a weekly close below 231. - Size for 207, stress-test at 190, and hold no buys above 254 and no other adds before December guidance.

FINAL TRANSACTION PROPOSAL: HOLD Neutral Analyst: You've both narrowed this a lot, so I'll start with what I'm taking back.

Conservative is right that I had one level doing two jobs. A resting buy at 247 and a trim trigger on a close below 247 tell two accounts opposite things at the same price. I'm dropping the 247 buy. The first sixth starts at 243 to 244, only about 4% below here, which a stock moving 3.35% a day reaches without much trouble. The rate and VIX source and the earnings date are also preconditions, not nice-to-haves. My RPO line was too loose, because 9% against 12.9% passes a deceleration. I'll take roughly 11% as the pass line, treat under 9% as a hard fail, and treat the zone between as no new money. If the filing doesn't explain an 18.8% jump in cost of revenue, that's an open question, and open means no new money.

Aggressive, the balance sheet read is the part I'd walk back. You said two of five tests already lean pass. The debt-to-equity of 0.58 on $11.76B of equity implies about $6.8B of debt. Total non-current liabilities are only $6.33B, and that bucket also holds long-term deferred revenue, tax and lease items. If that D/E figure is right, a meaningful slice of the debt is already in current liabilities, which fits Conservative's reading better than yours. It isn't a warning either. A maturity that needs refinancing is small against $9.35B of free cash flow and $4.4B of cash. So the borrowing test is neither a pass nor a worry yet. It's a number to read.

The leakage point needs the same caution. Conservative is right that $0.6B less cash can't explain $90M a quarter of lost interest income, though short-term investments aren't in our data, so I wouldn't be dogmatic. Tax is the likeliest cause. If it's permanent, it lowers the earnings growth that the 14.2x multiple rests on, so the gate should ask for the effective tax rate and whether the gap carries into FY27.

Now the point I think you've both buried. For two rounds the argument has been about a sixth of a position, which is about 3% either way. Meanwhile a holder at standard weight carries seven or eight times that risk. A drop to 207 is about 19% of the whole position, and 190 is about 25%. Aggressive calls the gate heavy machinery for a rounding error, and Conservative says stakes that small argue for a simpler process. Both are measuring the gate against the wrong thing. The filing read mostly informs the standard holding, not the sixth.

That exposes a hole. The weekly-close exit at 231 is written for the new money, and nobody has said what happens to the core. Let me say it now. The new block exits on that close, treated as gap-exposed. The core isn't auto-sold, because at 231 it's about 13x trailing earnings with a FCF yield over 10%. But that close should force a written re-underwrite within the week, defaulting to a one-third trim if the gate failed or the cause is Adobe-specific. A severe fail, meaning RPO under 9% with cost of revenue unexplained, should reopen whether standard weight is right at all. That gives the gate a downside branch, so it isn't theater.

Where I push back on Conservative is the second-sixth default. Requiring a market-wide drop with the index down, VIX up, software moving with beta and no AI headline is a configuration that almost never shows up in a year when software has traded on AI fear. Add a clean filing and nothing above 244, and the second sixth effectively never fires. That's the plan I called close to not owning the stock. The deeper point is fair, that a software-wide scare is the bear thesis showing up in price. But the test shouldn't be whether the letters AI appear in a headline. It should be whether anything changed in cash flows or estimates. So I'd keep Aggressive's split with Conservative's carve-out. Macro or generic sector selling with no Adobe-specific negative is eligible. A named AI substitution story, a creative-tools competitor release, a customer loss, a guidance leak or estimate cuts counts as Adobe-specific, so the answer is no.

I'd also add a rule neither of you offered: don't act on the alert bar. Run the checklist and buy the next session if it still reads clean. That's the human decision that answers the short-put worry. It will sometimes cost us a bounce, and I'll pay that.

On September, you're both partly right. The stock fell 9% from August 31 to September 4, sat flat through the heavy-volume days, then slid to 231. I can't tell from here whether that was the call or the tape. That's why the call transcript goes on the reading list before the checklist is finalized. If the call carried bad news, treating the next drop as sector beta is the wrong default. If it didn't, the same tape that lifted the stock 10% could drop it, and the checklist is built for that.

On the rest, we agree. Once the earnings date is confirmed, cancel resting orders about a week before the print. Holders face that gap anyway, and new money shouldn't add to it. Trim half the excess at 255 and above, ladder the rest at 262 to 267, and finish the trim on a daily close below the 10 EMA. That's 247 today, but it moves up if price does. Cap the total at standard weight, size the new block for 207 and stress it at 190, make no adds above 254 and no confirmation add before guidance.

So the middle is this. Read the 10-Q, release and call today against written numbers, with RPO near 11% to pass and under 9% to fail. On a pass, rest the first sixth at 243 to 244. Allow the second sixth only through a next-session checklist. Put one exit on the new block and write a plan for the core.

FINAL TRANSACTION PROPOSAL: HOLD Neutral Analyst: I'll start with what I'm taking from each of you, because there's more agreement here than the length of this thread suggests.

Conservative, the pre-print rule is the best addition of the round. Any excess above standard weight goes to standard a week before a confirmed date, and resting buys are cancelled then too. It's the first trim in this plan that doesn't depend on price cooperating, so I'm adopting it. I'll also count the block as a full third for risk budgeting from the first fill, since the budget has to exist before the second tranche does. And I'll take two clean sessions for the estimate check, because revisions lag a drop.

Aggressive, you said a plan where a pass never acts is abstention. I'd answer that the plan does act, and it acts where the exposure is. The first sixth is about 3% of a standard position either way, while the core and the excess are seven or eight times that. Trimming half the excess now, laddering the rest, taking what's left at market before the print, and re-underwriting the core on a weekly close below 231 are all actions. The gate informs those at least as much as it informs the sixth. Declining to buy on an open gate doesn't make the plan passive.

Now the disagreements. Conservative, your diagnosis of the second sixth is right, but the fix moves the problem. You said there's no room between 244 and 231 for two independent decisions, and a 241 alert is only 0.35 ATR below the first fill. But keeping 238 alone puts the second buy 7 points above the exit, under one ATR. That's the stop-out geometry we both rejected for fills at 231 to 235. So I'd drop 241 and keep 238, with a floor. If the stock is already below about 235 when the checklist runs, the answer is no. The second sixth then lives in a narrow window and will rarely fill. That's fine, because it's an option and December guidance is where the real sizing decision happens.

I also like your peer test in principle, but a point or two relative to a median is inside the noise. ADBE's own typical daily range is 3.35% of price, and the basket mixes very different betas. The one day the news grouped them, ADBE and ServiceNow rose 2% while Salesforce fell 2%, though that was acquirer-specific. Over one or two sessions a band that tight trips on noise about as often as on information. So keep it numeric, but set it from the trailing distribution of ADBE's two-day move relative to the basket, a bit over one standard deviation, and write it down before looking. That needs the same price source as the 10-year and VIX, so it joins the precondition list.

On unclear meaning a one-third trim of the core, I'll take it, since I made unclear mean no on the buy side and the symmetry is fair. But it can't be a one-way ratchet. The stock closed at 231 on September 28 and has risen 10% in three weeks. A rule that fires around that level, in an ADX-13 tape, sells near the bottom of a range and has no path back. So the trimmed third needs a stated return condition. It's eligible to come back when the cause is classified as macro or sector, or at December guidance, whichever is first. Those are fundamental triggers, not trend signals, so they don't contradict what we've said about trend signals.

On gaps, you keep citing June, from 218.80 to an intraday 190 in a week, as proof a weekly exit does nothing in a gap. True, but look at when the heavy-volume gaps fell: December 11, March 13, June 11 and 12, September 10 and 11. That's one per quarter, which looks like the print rhythm and is consistent with a December 9 date, though I can't confirm it. If so, the gap risk is concentrated in one scheduled window a quarter, and the pre-print rules answer it directly. The slide to 231 also played out over the two weeks after the September heavy days, not on them. That kind of move gives a weekly check time to act, and it would have fired near the low, which is the whipsaw argument again. So confirming the date is worth more than anything else on the precondition list. Until it's confirmed, use December 1 as the placeholder.

Aggressive, on your valuation line, 13x earnings at 238 holds up, because GAAP net income is already after stock comp. The 10% free cash flow yield doesn't, because FCF is before it. The honest statement is 13x GAAP and a 7% to 10% yield depending on what SBC turns out to be. I can't tell you whether 7% is attractive without the 10-year, which is a second reason to fix the data source first. I'd also back off writing the pass down as a reason to hold the core through noise. Write it as context for the re-underwrite, with an expiry at the print, not as a waiver from it.

On the net income leakage, you and Conservative are answering different questions. The level has sat between 76 and 78 cents of net income per dollar of operating income in all three FY26 quarters. That fits a step, as you say. But a step that persists is the base the 14x is paid on, as Conservative says. So the filing question is the effective tax rate and whether it's guided to stay, not whether the comparison laps.

So here is what I'd tell someone holding this. If you're flat or below standard weight, do nothing at 254 and do the reading against written numbers. On a pass, rest the first sixth at 243 to 244 and cancel it by December 1 or a week before a confirmed date. Run the alert at 238 with the floor and two clean sessions, and never go past standard weight. On a fail or an open question, buy nothing.

If you're at standard weight, hold and add nothing. A weekly close below 231 triggers a written re-underwrite, and unclear means a third comes off, with a stated way back.

If you're above standard weight, take half the excess at 255 and up and the rest at 262 to 267. Finish the trim on a daily close below the 10 EMA, which is 247 today. Anything still over standard goes at market a week before the print.

Any new block shares one exit on a weekly close below 231. Size it for 207 and stress it at 190, which for a full third is about 5% and 7% of a standard position.

What's left between you is narrow. Aggressive still wants the plan to buy a dip it can't yet classify. Conservative's plan comes close to never adding. This one moves where the risk is, and it adds only when evidence and price both pay for it.

FINAL TRANSACTION PROPOSAL: HOLD Neutral Analyst: You've both come a long way. A few rounds ago this was a fight over buying at 254. Now we all agree on a cap at standard weight, an RPO gate with 11% as the pass line and 9% as the hard fail, a first sixth at 243 to 244, and an excess trim that doesn't depend on price. We also agree on a one-third trim of the core when a weekly close below 231 has an unclear cause, and on no technical adds. What's left is mostly wording, so I'll test the wording. I think the bigger risk now is that the plan is too heavy to run. We have written tests, three data sources, a percentile peer band that excludes earnings windows, a basis-point rate rule, next-session execution, two clean sessions, a 235 floor and a 75% attribution test. All of that governs a tranche worth about 3% of a standard holding. Most of the machinery belongs around the core and the excess, which carry seven or eight times the risk.

Aggressive, your June point is right, and there's a fact that makes it stronger. The 231.01 close was a Monday. The Friday close that week isn't in our data, but the stock was 249.52 the Monday before and the MACD histogram turned positive on October 8. As far as I can reconstruct, there hasn't been a weekly close below 231 since the June washout. So the exit is rare and slow, closer to a check on the higher low than a stop. That supports your whipsaw argument, but it also means the exit does nothing in a gap. We should keep treating it as a thesis check, size for 207, and stop expecting it to protect anything.

I agree a pass branch that can never buy anything is abstention. The post-print branch needs the same treatment, or the trims have no way back. But your "even if above 254" skips Conservative's point that price pays for evidence in the first session. I'd split it the way we split the pullback. Evidence earns back the trimmed core, because that's size we already underwrote, after the numbers pass and two sessions have gone by. Price has to earn the extra sixth, either on a pullback or after the 10-K. Selling the excess before the print is also insurance, not a free lunch. If December is clean and the stock gaps up, that's the premium, and we shouldn't relitigate it.

Conservative, I agree the way back should be mechanical, but your version has a whipsaw. A weekly close back above 231 is the same line as the exit, and a stock with 3.35% daily ATR can close at 230 one Friday and 232 the next. That sells and rebuys the same third within a fortnight. Put the return about an ATR above the exit, at a weekly close above roughly 240, which is also near the Bollinger midline. December guidance is the backstop. That keeps your two clean sessions, makes it slower than the way out, and avoids the churn.

On the gate, I've said a gate that can't fail is theater, but one that fails on boilerplate is theater in the other direction. A 10-Q usually names cost-of-revenue drivers in a sentence or two and rarely attributes three quarters of the dollars. Make the test about named drivers, direction and whether they recur, and let the call fill gaps. Otherwise "open" gets triggered by the filing's writing style, and we've decided open means no.

I'd also soften the buyback point. A 10% higher price cuts a roughly 9% gross share shrink to about 8.2%, so net shrink goes from 7% to about 6.2%. That's under a point and second order. Financing outflows were about 91% of nine-month free cash flow, so the buyback is running near FCF, not ahead of it. The cash drawdown comes from the investing line stacked on top.

I have two things neither of you has raised, and both come from memory, so verify them. First, I recall Adobe announcing an all-cash purchase of Semrush last November for about $1.9B. Nothing in our pull confirms it or says when it closed. If it did close, it fits the near-doubling of investing outflows. It would also mean a point or so of the 12.9% growth isn't organic. Acquired RPO would flatter the 11% line, and some of the cost-of-revenue and opex growth would be acquired costs and amortization. That makes "organic within a point of reported" the wrong test. Better to ask whether organic growth is at least last year's 10.7% pace and whether RPO ex-acquisition clears the same lines.

Second, my recollection of the 2026 Fed calendar is meetings on October 27-28 and December 8-9. That would put the December decision on the same day as the rumored Adobe print, and a rate decision a week from now. If that holds, finish the reading this week but don't arm the first-sixth order until after the October decision. The cost is a week. The benefit is not leaving a resting buy through the rate event we can't see, since FRED is down. The December 1 cancel date covers both December events.

So the plan I'd stand behind is this. If you're flat or below standard weight, buy nothing at 254. Finish the reading against the written numbers, with organic and ex-acquisition adjustments and the call included. On a fail or a named open item, there's no new money. On a pass, and after the October decision if the date holds, rest the first sixth at 243 to 244 and cancel it by December 1 or a week before the confirmed print. Decide on a second sixth at 238 by hand, next session, with a short written checklist and a peer band set once. Total exposure never goes past standard weight, and the new block exits together on a weekly close below 231, sized for 207 and stressed at 190.

If you're at standard weight, hold and add nothing. A weekly close below 231 triggers a written re-underwrite, with a third trimmed by default if the cause is unclear. The third returns on a weekly close above about 240, or at December guidance, whichever is first.

If you're above standard weight, take half the excess now, ladder the rest at 262 to 267, and finish on a daily close below the 10 EMA, which is 247 today. Whatever is still above standard goes at market a week before the print.

Aggressive gets a path that buys when evidence and price both pay. Conservative gets protection where the real exposure sits, in the core and the excess. Neither has to pretend a sixth-sized tranche decides the outcome.

FINAL TRANSACTION PROPOSAL: HOLD

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Hold

Executive Summary: Hold ADBE at $254.62. Do not add at or above $254: the probability-weighted target of $265 (about +4%) is well below a ~10% hurdle for a 1.415-beta stock whose margin and conversion drags have not turned. If you hold above standard weight, trim half the excess at $255+ now, ladder the rest at $262-267, finish the trim on a daily close below the 10 EMA (~$247), and sell any remaining excess at market a week before the print (by Dec 1 if the date stays unconfirmed). If you are flat or underweight, build at most one-third of a standard allocation, and only after the Q3 10-Q, release and call pass pre-written numeric tests: a first sixth at $243-244, a manually checked second sixth near $238 (nothing below $235), never above standard weight, one gap-exposed exit on a weekly close below $231, and sizing for a slide to $207 (stress case $190).

Investment Thesis: DECISION. All three risk analysts, the Research Manager and the trader land on Hold. This is not a compromise to avoid conflict. After weighing the debate, neither direction has an edge at $254.62. What remains in dispute is entry price and the size of a tranche of one-third or less, not direction. BULL EVIDENCE THAT SURVIVED. (1) 14.2x trailing GAAP EPS of $17.91, a ~7.0-7.3% after-SBC earnings yield. (2) Revenue growth of 12.0%, 12.7% and 12.9% over Q1-Q3 FY26. (3) Diluted shares down ~6.7% YoY. (4) TTM FCF of $9.35B. (5) Net debt only ~0.25x EBITDA. (6) Financing outflows ~91% of 9-month FCF versus above 100% a year earlier. Aggressive's cross-check also holds: 13.3x GAAP at $238 is ~7.5% earnings yield, and EPS growth of ~13-15% if net income converges toward operating-income growth implies a PEG near 1. That is fair value, not a bargain. BEAR EVIDENCE THAT WON THE SPECIFIC EXCHANGES. (1) Net income grew only +4.3%, +1.2% and +3.1% while EPS grew +11.1%, +7.9% and +10.5%, so roughly 7 of ~10 EPS points come from buybacks. (2) Gross margin went +50, +10 and -60 bp YoY while cost of revenue growth rose from 6.8% to 12.1% to 18.8%. Q3 cost of revenue was ~$764M versus ~$641M. (3) Operating margin was -150 bp YoY. Conservative showed ~90 bp of that comes from opex growing 14.8% against 12.9% revenue, a line nobody had tested. (4) Net income was 77.6% of operating income versus 81.5%, about $90M a quarter. Lower interest income cannot explain it, and tax is likely but unverified. (5) Neutral's arithmetic: D/E of 0.58 implies ~$6.8B of debt against only $6.33B of total non-current liabilities, so some debt has probably moved current. That would also explain current liabilities rising $2.65B and the 0.77 current ratio. (6) The 9.4% FCF yield is pre-SBC. Aggressive's generous $2.5B SBC case gives ~6.9%. (7) The multiple swung 11.1x, 16.8x, 12.9x and 14.2x in sixteen weeks, and the ~12.9x breakeven was the 9/28 close. TECHNICALS. Price sits under a 254.98-257.63 resistance cluster: upper Bollinger, the 50 SMA at 255.67, and the daily SuperTrend at 256.93 (down). ADX is 13.14 (no trend) and the daily z-score is +1.95. Reward-to-risk to the 265.60-266.51 shelf against a 2xATR stop at 237.56 is ~0.7:1. The weekly SuperTrend is up (stop 206.08). The monthly stop at 401.26 sits above the 52-week high, so it is uninformative. ADJUDICATION. Aggressive withdrew the 4-point risk at $235, the claim that two of five tests already lean pass, and the pre-SBC 10% yield at $238. Aggressive was right that a pass branch must be able to act and that December needs a written re-risk path. Conservative was strongest on four points: a gate must be able to fail; $247 cannot be both a buy level and the 10 EMA trim trigger, so the $247 buy is dropped; excess should go to standard before the print regardless of price; and the way back after a trim must be mechanical. Neutral's decisive point is that a standard holding carries 7-8x the risk of a sixth. A full third bought at $244 loses ~15% at $207, about 5% of a standard position, and ~22% at $190, about 7.4%. Most of the risk control therefore belongs on the core and the excess, which is how the plan is built. GATE (written before reading). (a) Organic growth clearly at or above ~11% and not decelerating from 12.0%. Neutral recalls a ~$1.9B Semrush deal that is not in our data. If it closed, adjust revenue and RPO for it, and treat ~11.1% as a fail. (b) RPO/deferred revenue growth: ~11%+ passes, under 9% is a hard fail, and anything between means no new money. © Named, recurring-or-not drivers for both cost of revenue (+18.8%) and opex (+14.8%). (d) Effective tax rate, and whether the ~4-point conversion gap persists into FY27. (e) Composition of current liabilities, debt maturities and buyback funding. (f) The ~$1.7B non-capex investing outflow. A fail or a named unanswered item means no new money. Before arming any order, also confirm working 10-year and VIX sources (FRED failed), the print date (~Dec 9, unconfirmed) and the FOMC date (Oct 27-28 per Neutral's memory). If that FOMC date holds, arm nothing until after it. CORE RULES. A weekly close below $231 forces a written re-underwrite within the week. If the cause is unclear, trim one-third by default. That third returns on a weekly close above ~$240, or after a clean December guide plus two sessions. A clean post-print read restores the trimmed core first, and any extra sixth must still be earned on price. WHAT CHANGES THE RATING. A clean filing plus a fill in $241-244 moves it to Overweight. A failed gate moves it to Underweight. In December, a CLEAN print allows adding toward standard in tranches. CLEAN means: gross margin down 30 bp YoY or less; organic growth ~11%+; an FY27 guide with flat-to-up operating margin; and the conversion slip explained. A BAD print means exit any starter and cut the core to half standard. BAD means any of: organic growth under 11%; operating margin compression beyond 150 bp; gross margin worse than -60 bp; COGS growth above 20%; or financing outflows above FCF with rising debt. PRICE TARGET ($265, valuation method). 6-month EPS = 17.91 x 1.05 = ~18.81, using half of the ~10% annual EPS path (~3% net income growth plus ~7% share shrink). Scenarios: constant 14.2x gives ~$267.1; drags persist and the multiple goes to the 12.9x breakeven, ~$242.6; clean print and a 16x rerate, ~$301.0. Weighting them 55/30/15 gives 146.9 + 72.8 + 45.2 = ~$264.9, about +4% from $254.62. That sits inside the Research Manager's +1-5% expected-return band, below the ~10% hurdle, and just under the 265.60-266.51 resistance. DATA GAPS that lower confidence: the 10-Q was not read; there is no RPO, deferred revenue, SBC, debt or buyback detail; FRED failed; rate odds come from thin Polymarket markets; Semrush, the FOMC dates and the print date come from memory; and the 10/21 bar is provisional.

Current Price: 254.62

Price Target: 265.0

Confidence: Medium

Time Horizon: 3-6 months (re-rate after the Q3 10-Q read and at the mid-December Q4/FY27 print)